学術研究 – ページ 17 – ワールドソルーションズLLC

Germany ドイツ Vol.5（pharmaceutical corporations 製薬会社）

All the below link and tweets are in English.

取り急ぎ以下貼っておきます。

Germany Vol.23 (pharmaceutical corporations: BioNTech)

上記リンク内に無い本日までのツイート

We provided an update on the potential timelines for the #COVID19 #vaccine candidate BNT162b2. We will seek approval only if the data provides a clear picture in three key areas: safety, efficacy, manufacturing quality. Read more in @WSJ by @bopanc. https://t.co/62njuhX3lu

— BioNTech SE (@BioNTech_Group) October 16, 2020

We are excited to welcome the latest addition to the BioNTech family: our colleagues in Marburg. The tech transfer is currently being made and we plan to start the production of potential #COVID19 vaccines in 2021. Welcome to #TeamBioNTech! pic.twitter.com/o9N26LmRoD

— BioNTech SE (@BioNTech_Group) November 2, 2020

One of the German #biotech firms working on a #CoronaVaccine, @BioNTech_Group, says results from study on effectiveness to come within next few days. Together with partner @pfizer will apply for FDA approval in 2 weeks. More on German vaccine development:https://t.co/cc92465OxM pic.twitter.com/YqwjNQds6O

— Germany Trade & Invest (@GTAI_com) October 30, 2020

https://twitter.com/InvestFlanders/status/1323176383582011394

Personalized #NeoantigenTherapy Plus #AntiPD1 | A Phase Ib Trial in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer | Lakshmi Srinivasan @BioNTech_Group @CellCellPress https://t.co/9NtpX0r8Bt | #2020_ReCapOct pic.twitter.com/2St8j5L624

— McHeyzer-Williams (@mmw_lmw) November 1, 2020

Engage with the community transforming the biotech sector at #BioIntegrates. Our one-day event will include interviews with Steve Bates, CEO, @BIA_UK and Sean Marett, Chief Business and Commercial Officer, @BioNTech_Group. Discover the full agenda: https://t.co/qynIgPU7rB pic.twitter.com/yJH4LzKuT2

— Life Science Integrates (@LSIntegrates) October 30, 2020

“The @UniofOxford/@AstraZeneca vaccine is expected to be one of the first from big #pharma to secure regulatory approval, along with @pfizer and @BioNTech_Group’s candidate" #ScienceNews #covid19news https://t.co/LgDPb8Eib4

— Life Science Rec. (@ScienceJobs) October 29, 2020

Comprehensive summary about the mRNA vaccine made in Mainz by Ugur, Özlem and the whole team of @BioNTech_Group and @tronmainz https://t.co/oqBicNHKrK

— Sebastian Boegel (@sebboeg) October 27, 2020

How a Little-known German Biotech Firm Founded by the Children of Turkish Immigrants Became a Leader in Global #Coronavirus Vaccine Race. ⁦My report via ⁦@WSJ⁩: https://t.co/FcSyXVccnC

— Bojan Pancevski (@bopanc) October 22, 2020

https://twitter.com/en_germany/status/1317834581048020993

@pfizer will apply for EUA from @US_FDA soon after they achieve the safety milestone of their experimental vaccine (developed with @BioNTech_Group) in the third week of November: https://t.co/WUtZ1UGrg5 #XerayaCapital #IndustryUpdates #COVID19 #Vaccine #Coronavirus pic.twitter.com/MQhAtL10oD

— Xeraya Capital (@xerayacapital) November 3, 2020

I continue to be #PfizerProud of all our colleagues, who delivered another strong quarter during these challenging times. The global phase 3 study for our #COVID19 vaccine candidate w/ @BioNTech_Group is ongoing at 150 sites with more than 42,000 participants enrolled. pic.twitter.com/ZCIzGMEDcJ

— AlbertBourla (@AlbertBourla) October 27, 2020

We are proud to organize the virtual @mrnaconference, the premier meeting destination for industry and academic professionals to explore the rapidly advancing science and business of #mRNA medicines. @BioNTech_Group @CureVacRNA @moderna_tx #eventplanning #vaccine #COVID19 pic.twitter.com/oKuuC0GpYA

— INTERPLAN Congress, Meeting & Event Management AG (@interplan_de) October 28, 2020

Richard B. Gaynor, MD, chair of the Accelerating Cancer Cures Advisory Committee, Damon Runyon board member, and President and Chief of Research and Development @BioNTech_Group U.S welcomes us to the virtual #CancerCures20 Symposium! pic.twitter.com/lArIzBNXKC

— Damon Runyon Cancer Research Foundation (@DamonRunyon) October 28, 2020

“@JNJNews plans to start testing its experimental #COVID19 #vaccine in youths aged 12 to 18 as soon as possible… Rival drugmaker @Pfizer has already begun testing the COVID-19 vaccine it is developing with Germany's @BioNTech_Group in children as young as 12.” #compliance https://t.co/PD9QxUCPag

— Mark Warner (@MAAWLAW) October 30, 2020

.@BioNTech_Group uses same mRNA technology as @moderna_tx. It never worked on anything, certainly not on vaccines, yet here we are.
Briefly discussed here: https://t.co/ccMuKcZYgi

— Leonid Schneider (visit my site for Covid19 cures) (@schneiderleonid) October 27, 2020

ツイッター検索で上記製薬会社名及び Japan や日本の5製薬会社各社名を入れて出て来たもの

We announced an agreement with #Japan for 120m doses of our mRNA-based vaccine candidate. This is part of our commitment to address the global health crisis together with @Pfizer as we hope it may help in bringing the world together at the #TokyoOlympics. https://t.co/YUmpvqELru pic.twitter.com/VcubAIgTvd

— BioNTech SE (@BioNTech_Group) July 31, 2020

Pfizer, BioNTech start combined trials of COVID-19 vaccine candidate in Japan https://t.co/nR8eZ56zeB pic.twitter.com/yyabGBd1x2

— Reuters (@Reuters) October 20, 2020

Pfizer, BioNTech to supply 120 million doses of coronavirus vaccine to Japan https://t.co/CPE5UL5WWR pic.twitter.com/iphKs1StYM

— Reuters (@Reuters) July 31, 2020

Pfizer Inc and BioNTech SE announced on Tuesday the start in Japan of combined Phase I and Phase II clinical trials of their mRNA vaccine candidate against the coronavirus.https://t.co/jm6bN39Is7

— Hindustan Times (@htTweets) October 20, 2020

Pfizer, BioNTech start combined trials of #COVID19 vaccine candidate in Japanhttps://t.co/jm6bN2S73x pic.twitter.com/TiA3mzGXfn

— Hindustan Times (@htTweets) October 20, 2020

Japan to get 120 mn doses of #COVID19 vaccine from Pfizer, BioNTechhttps://t.co/dVvgeYAlhU pic.twitter.com/P8U5kvtWr7

— Hindustan Times (@htTweets) July 31, 2020

Russia says its secretive Covid-19 vaccine is “a Sputnik moment” – ready to be launched in less than 2 weeks.

As some countries develop their own, others are both making and buying vaccines, including Japan which is procuring 120M doses from Pfizer and BioNTech pic.twitter.com/pHRmIAQSGs

— TRT World (@trtworld) July 31, 2020

Today we announced an agreement with the Ministry of Health, Labor and Welfare in #Japan to supply 120M doses of our #COVID19 #vaccine candidate in collaboration with @BioNTech_Group, subject to regulatory approval: https://t.co/FBbQN3ciRF pic.twitter.com/U402NeO6WA

— Pfizer Inc. (@pfizer) July 31, 2020

We’re committed to helping governments have access to breakthroughs. Today we announced an agreement w/ Japan to supply, subject to regulatory approval, 120M doses of the mRNA-based COVID-19 vaccine candidate being co-developed by @Pfizer & @BioNTech_Group https://t.co/PmZEsrCRgZ

— AlbertBourla (@AlbertBourla) July 31, 2020

Pfizer and BioNTech agreed to provide Japan with 120 million doses of the Covid-19 vaccine they’re developing https://t.co/EGTGMDOuVl

— Bloomberg Technology (@technology) August 1, 2020

Pfizer, BioNTech to make 120M vaccine doses for Japan https://t.co/6JkbuzH5ug pic.twitter.com/ZYhPQd5dv9

— BNN Bloomberg (@BNNBloomberg) July 31, 2020

PFE Stock Down 0.5%, Pfizer and BioNTech to Supply Japan with 120M Doses of COVID-19 Vaccinehttps://t.co/UXUi8CUCgI pic.twitter.com/eYc2Wj14qd

— Coinspeaker (@coinspeaker) July 31, 2020

• Japan signs deal to secure 120 million dose of potential coronavirus vaccine, German pharmaceutical group BioNTech says https://t.co/XrAeG2tzpX

— ABS-CBN News (@ABSCBNNews) July 31, 2020

Pfizer $PFE, BioNTech $BNTX to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidate https://t.co/Cww2CVC5jT pic.twitter.com/s2u8FoJU78

— Streetinsider.com (@Street_Insider) July 31, 2020

Pfizer, BioNTech score deal to supply 120M Covid-19 vaccine doses to Japan, writes @biotechvisigoth @medcitynews https://t.co/PSX9S2pMiz @BioNTech_Group $PFE $BNTX #COVID19

— MedCity News (@medcitynews) August 3, 2020

New post: Pfizer and BioNTech Supply Japan with 120 Million Doses of COVID-19 Vaccine Candidate BNT162 https://t.co/DLWtW6YYRt

— BiopharmaMASH (@bio_mash) August 1, 2020

Pfizer and BioNTech to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidate https://t.co/VajfZkzqfz @pfizer @BioNTech_Group More Transatlantic Life Science Business News at [LSUS] at https://t.co/HEEySVwfoy pic.twitter.com/PAdjZEeYAm

— [iito] Life Science (@iitoLifeScience) July 31, 2020

The #Covid19vaccine partnership of @BioNTech_Group and @pfizer inked its third supply pact in a week on Jul. 31. The #Japan government will take 120 million doses at an undisclosed price in the 2021 first half. It is the companies’ first #Asian agreement. https://t.co/jMHYIycNDk

— CHEManager International (@CHEManager_EU) August 4, 2020

US strikes $2.1bn #Covid19 vaccine deal with Sanofi $SAN and Glaxo $GSK, while Pfizer $PFE and BioNTech $BNTX to supply Japan with 120m vaccine candidate doses. More on the vaccine race in our podcast episode ➡️ https://t.co/LMsp4FXrx9 https://t.co/lOlbukINDP

— IGTV (@IGTV) July 31, 2020

Japan has signed a deal to secure 120 million doses of a potential coronavirus vaccine, German pharmaceutical group BioNTech, which is developing the drug with US pharma giant Pfizer, said Friday. | @AFP https://t.co/d9cryfWhNC

— Inquirer (@inquirerdotnet) July 31, 2020

Japan has signed a deal to secure 120 million doses of a potential coronavirus vaccine, German pharmaceutical group BioNTech, which is developing the drug with US pharma giant Pfizer, said. https://t.co/crihB500gj

— Philstar.com (@PhilstarNews) August 1, 2020

Japan has signed a deal to secure 120 million doses of a potential coronavirus vaccine, German pharmaceutical group BioNTech, which is developing the drug with US pharma giant Pfizer, said Fridayhttps://t.co/v8o7oVWaA0 pic.twitter.com/M0IDFS0Egu

— AFP news agency (@AFP) July 31, 2020

Pfizer, BioNTech to supply 120 million doses of COVID-19 vaccine to Japan https://t.co/bqSgv5pZnW

— Business Today (@BT_India) July 31, 2020

#Japan signs deal with #BioNTech to secure 120 million doses of potential #coronavirus vaccine#TheNews

— The News (@thenews_intl) August 1, 2020

Pfizer, BioNTech to supply 120m doses of virus vaccine to Japan.https://t.co/G8kN9ZwzaV

— Nikkei Asia (@NikkeiAsia) July 31, 2020

Pfizer, BioNTech to supply 120 mil doses of experimental coronavirus vaccine to Japan: Pfizer Inc and BioNTech SE have agreed to supply Japan with 120 million doses of their experimental coronavirus vaccine in the first half of 2021, the companies said… https://t.co/A5YL4MaTnk

— Japan Today News (@JapanToday) July 31, 2020

COVID-19 Vaccine Pipeline https://t.co/z9QJ2v4RBj via @kyodo_english #WHO @moderna_tx #NIAID @InovioPharma @BioNTech_Group #ClinicalResearch "Even if overseas vaccines have success and received special regulatory approval, the supply in Japan will be limited"

— ClinicalBid (@ClinicalBid) June 1, 2020

Japan signed a deal to secure 120 million doses of a potential coronavirus vaccine, German pharmaceutical group BioNTech said Friday, July 31.

FULL STORY: https://t.co/eVEI6JXlcN pic.twitter.com/F8l7Ze6UUl

— Rappler (@rapplerdotcom) August 1, 2020

BioNTech says the first deliveries to Japan are planned for the first half of 2021. https://t.co/SjcHtrTMy2

— Rappler (@rapplerdotcom) August 1, 2020

Takeda estimates £162.50 million hit to operating loss as Novartis withdraws from European approval for Xiidra. #TakedaPharmaceutical #Novartis #EMA #BionTech #StockMarketNews #Coronavirus #Xiidra #OperatingLoss #Asia @EMA_News https://t.co/qgyUjrECut pic.twitter.com/8m4LRpX2I3

— iNVEZZ (@InvezzPortal) June 29, 2020

Boston Globe story yesterday on how small businesses in Central Square, #CambMA have been impacted by covid-19. https://t.co/ItouzHJizj. Biopharma companies in Central Sq incl Novartis, Takeda, Blueprint, Spero, Voyager, Beam, AbbVie, Fulcrum, Rheos, Neon/BioNtech, Intellia

— Pearl Freier (@PearlF) September 6, 2020

Takeda teams up with Novavax to introduce its coronavirus vaccine in Japan | @Takedapharma @Novavax @Pfizer @BioNTech @AstraZeneca @UniofOxford #Vaccines #Covid19 #Biotech #MatrixM #Maryland #OperationWarpSpeed @JNJ https://t.co/82tpoKazFb

— Aspen Biosciences (@aspenbio) August 9, 2020

This week's EuroBiotech Report—Novo-Ablynx, Takeda-TiGenix, Scancell-BioNTech, Sanofi-Alnylam and Boehringer https://t.co/k5jkrKtv4M

— FierceBiotech (@FierceBiotech) January 11, 2018

U.K. イギリス Vol.31（pharmaceutical corporations 製薬会社）

All the below link and tweets are in English.

取り急ぎ以下貼っておきます。

UK Vol.170 (pharmaceutical corporations: GlaxoSmithKline)

上記リンク内に無い本日までのツイート

Today we, together with @Sanofi and @Gavi, announced a Statement of Intent to make available 200m doses of our Sanofi/GSK co-developed #COVID19 #vaccine to the COVAX Facility, if successful in clinical trials. Learn more: https://t.co/OYGgP1QpVk pic.twitter.com/pnKYUy15Dq

— GSK (@GSK) October 28, 2020

Our intent to supply the COVAX Facility (led by @gavi and @WHO) with 200m doses of our co-developed #COVID19 #vaccine, if successful in clinical trials, is key to ensuring equitable access for every country in the world and protecting those most at risk. https://t.co/CcPiEsruRN pic.twitter.com/ufnuOfxVJ3

— GSK (@GSK) October 28, 2020

Our recent announcement that we will make available 200m doses of the #vaccine we’re co-developing with @Sanofi to COVAX, could, if successful in clinical trials, be a key milestone to helping end this #COVID19 #pandemic. https://t.co/aje70UKtQz

— GSK (@GSK) October 29, 2020

Interesting insights from global experts on #pandemic prevention and preparedness, including the role of #vaccines, as we learn from #COVID19. (Subscription may be required). https://t.co/AgxJLWB3rA

— GSK (@GSK) October 30, 2020

We are proud to join @ScienceMagazine Top 20 Employers. Testament to bringing together great science, new tech, and outstanding people. @ScienceCareers #Innovation #SCTopEmployer pic.twitter.com/VzLEyNRS9I

— GSK (@GSK) October 31, 2020

Thanks to our own @EstOdek for highlighting what needs to happen so #BIPOC are represented, visible & celebrated in #Science. We’re inspired by her to continue building an inclusive environment where all scientists feel valued & can bring their best and authentic selves to work! https://t.co/5QdufNCgm7

— GSK (@GSK) October 30, 2020

Collaboration in the wake of #COVID requires trust. Our CSO Hal Barron talks about how our partnership with @Vir_Biotech came together in 18 days and why focus on critical issues is key in the @WSJ article: https://t.co/M8aC4lyR4a pic.twitter.com/2YkaIyu0pP

— GSK (@GSK) October 24, 2020

Our CSO Hal Barron and President of Global Vaccines Roger Conner spoke with @joewalkerWSJ about how #COVID19 is ushering in a new era of industry collaboration. https://t.co/hkKwkyLzEb

— GSK (@GSK) October 24, 2020

#DYK Most adults in the US aren't vaccinated against #HepA? #Hepatitis A can be transmitted through close contact w/ an infected person or through contaminated food or water. Talk to your doctor about vaccination.
Visit ➡️ https://t.co/cEV0x0F39t #LiverAwarenessMonth #NOhep pic.twitter.com/MVI3DVzUZO

— GSK US (@GSKUS) October 27, 2020

We’re supporting the voice of the patient by working together to eliminate access barriers at the Alliance for Health Policy, Voice of the Patient Health Summit 2020. #AHPSummit20 #patientvoice https://t.co/vki0yDOUVo

— GSK US (@GSKUS) October 26, 2020

Sanofi and @GSK have signed a Statement of Intent with the @gavi @WHO @CEPIvaccines #COVAX facility to secure the distribution of our #COVID19 vaccine worldwide: https://t.co/NB1oald3wH #SanofiActs pic.twitter.com/BXD2sLoh0h

— Sanofi (@sanofi) October 28, 2020

This year has shown unprecedented collaboration across our industry. Congratulations, John Shiver, SVP of R&D, @sanofipasteur, in partnership with @GSK, on being named one of @FiercePharma’s most influential people in the fight against #COVID19. https://t.co/I458tte4iO

— Sanofi US (@SanofiUS) October 27, 2020

Today we are proud to announce our intent to supply 200 million doses of our adjuvanted recombinant protein #COVID19 vaccine, if approved to #COVAX alongside @GSK. This will help offer timely and cost-effective access to vaccines worldwide.@gavi Learn more https://t.co/uRDSulc3zb pic.twitter.com/JrWpcOrGqu

— Sanofi Pasteur (@sanofipasteur) October 28, 2020

We are extremely proud of John Shiver, Senior Vice President of Vaccines Global R&D, for being named by @FiercePharma as one of the most influential people in the fight against #COVID19, in partnership with @GSK. https://t.co/LAIf0GT1Pr

— Sanofi Pasteur (@sanofipasteur) October 27, 2020

We’re pleased to announce we have signed a Statement of Intent to procure 200 million doses of the @Sanofi and @GSK #COVID19 vaccine candidate for the #COVAX Facility! https://t.co/4Pv6BtXFtn @CEPIvaccines @WHO

— Gavi, the Vaccine Alliance (@gavi) October 28, 2020

Very pleased that @Gavi has signed a Statement of Intent with @Sanofi and @GSK to provide 200 million doses of their adjuvanted recombinant protein #COVID19 vaccine to the #COVAX Facility! https://t.co/pUO6ntVnLR

— Seth Berkley (@GaviSeth) October 28, 2020

Thank you @sanofi for your partnership and commitment alongside @GSK to ensure that safe and effective #COVID19 vaccines reach those in greatest need around the world. Pleased to welcome your commitment to the #COVAX goal of equitable vaccine access. #OneWorldProtected https://t.co/QraLhRsyVZ

— Seth Berkley (@GaviSeth) October 28, 2020

Thank you @GSK for working with @Sanofi to help ensure the most at-risk groups, such as healthcare workers, have rapid access to doses of #COVID19 vaccines. I welcome your commitment to global health security! #OneWorldProtected https://t.co/DmS1X7Vwea

— Seth Berkley (@GaviSeth) October 28, 2020

https://twitter.com/scibus/status/1321454739364728834
https://twitter.com/MSF_access/status/1321890170808008706
https://twitter.com/MSF_access/status/1321935282971807744

MSF calling for transparency from pharmaceutical corporations around price, supply and distribution of the potential future #COVID19 vaccine @GSK @sanofipasteur https://t.co/bvbHBaHvsT

— Shailly Gupta (@Shaillytweeting) October 29, 2020

Pharmaceutical giant @GSK will attend this year’s China International Import Expo. So what's the latest from #GSK on developing a #COVID19 #vaccine? And What are the highlights of their new products and services this year? pic.twitter.com/LjTM34TvhI

— Frontline (@Frontlinestory) October 29, 2020

EU approves Zejula as monotherapy in ovarian cancer @GSK https://t.co/hwtquaFAOL pic.twitter.com/JZbY6VsktN

— The Pharma Letter (@ThePharmaLetter) October 30, 2020

Sanofi & GSK to supply 200m doses of their Covid-19 vaccine to global distribution scheme

Read it here: https://t.co/fiz2Tjk0vK @sanofi l @GSK l @gavi pic.twitter.com/cpmV0nOaXB

— EPM Magazine (@EPM_Magazine) October 29, 2020

https://twitter.com/UN_SPHS/status/1321745134149656576

COVID-19 Vaccine Update: Sanofi, GSK to Supply COVAX with 200 Million Doses of Coronavirus Vaccinehttps://t.co/mPLw6qMCC5 #COVID19Vaccine @sanofi @GSK #COVAX

— LatestLY (@latestly) October 29, 2020

The CEO of SBC Member Organisation @GSK is optimistic that a COVID-19 vaccine could be widely available in 2021. Find out more here:https://t.co/HmZgQgjY3w #COVID19 #covidvaccine pic.twitter.com/nREQEZsV93

— StevenageBioscience (@SteBioCat) October 28, 2020

Partner of #DMTR pic.twitter.com/LZPuOiyZlS

— riddler (@riddler_smitb) October 28, 2020

News for #pharma #marketers: Thurs, Oct 29

– @Sanofi, @GSK give 200 million COVID-19 vaccine doses to Covax
– @Pfizer will not report coronavirus vaccine results this month
– Podcast: @Genentech’s Quita Highsmithhttps://t.co/W779ysMOAh

— MM+M Magazine (@MMMnews) October 29, 2020

Dave Tudor and John Arthur of the Medicines Manufacturing Innovation Centre mark the start of construction of the MMIC today – exciting times for UK Life Sciences, manufacturing and Scotland! @Ivan_McKee @ukCPI @UniStrathclyde @GSK @AstraZeneca @scotent https://t.co/7LUCJl1Qpv pic.twitter.com/7zRN1fCmy5

— Life Sciences Scot (@LifeSciScot) October 26, 2020

White House “Vaccine Czar” Dr. Slaoui is using loopholes and working under a shady contract to skirt ethics laws that would require him to sell all his stock in COVID vaccine manufacturers. @RepKatiePorter and I want @GSA_OIG to investigate his contract.https://t.co/6EMTPBd9RN

— Elizabeth Warren (@SenWarren) October 30, 2020

https://twitter.com/TomDoddFCDO1/status/1321891577317511169

Construction has started on the Medicines Manufacturing Innovation Centre – a collaboration between Strathclyde, @ukCPI & industry partners @AstraZeneca & @GSK. The new centre will put Scotland at the cutting edge of advanced pharmaceutical manufacturing.https://t.co/4DJIQBQk3q pic.twitter.com/mdcz8iWBAm

— University of Strathclyde (@UniStrathclyde) October 28, 2020

Thanks to UCL for a charming virtual graduation ceremony ⁦@ucleastman⁩ ⁦@ucl_slms⁩ Thanks to ⁦@GSK⁩ and ⁦@basem_uk⁩ ⁦@PaedDentEastman⁩ ⁦@IanNeedleman⁩ for supporting Dr Julie Gallagher on her journey pic.twitter.com/kHemprO2oC

— Oral Health in Sport (@oralhealthsport) October 29, 2020

Get to know some of the #SCTopEmployers in #biotech #pharma and find job opportunities—Explore the 2020 Top Employer Profiles for @GSK, @Roche, and @pfizer:https://t.co/EsP0urWYqx pic.twitter.com/mR7pv1ZvEZ

— Science Careers (@ScienceCareers) October 30, 2020

Congrats @GSKUS @GSK ! pic.twitter.com/4kZMvS5V0Q

— Talend (@Talend) October 29, 2020

Congratulations to @CondeNast, in partnership with @tweetPHM on behalf of @GSK, for winning the Online Video or Film category for their work on “Well, Actually”!#DPIWeek2020 #FierceAwards #BeFierce pic.twitter.com/l0dZPLZJmx

— Digital Pharma (@DigitalPharma) October 28, 2020

Impressive presentation of Prof. Koen Kas, @kaskoen, at the @GSK meets Belgian University Event, talking about several #digital examples to turn sick care into #Healthcare! https://t.co/tWpJXVPQgc

— FlandersVaccine (@FlandersVaccine) October 27, 2020

Thank you @Amgen, @chemocentryxinc, @genentech, @GSK and @sanguinebio for sponsoring our Newly Diagnosed Patient conference happening this Saturday! Come see for yourself how their support is already giving vasculitis patients a better quality of life. pic.twitter.com/LsUrh5Y9Ar

— Vasculitis Foundation (@VasculitisFound) October 29, 2020

500 followers up! Shout out to our amazing @AI4VBH industry partners – thank you for all support so far!@ainostics @Biotronics3D @CydarMedical @GEHealthcare @innersightlabs @KheironMedical @MiradaMedical @NetAppUK @nvidia @PerspectumGroup @SiemensHealth @GSK pic.twitter.com/RfPYGgQzVe

— London AI Centre for Value Based Healthcare (@AI4VBH) October 28, 2020

ツイッター検索で上記製薬会社名及び Japan や日本の5製薬会社各社名を入れて出て来たもの

.@GSK and Daiichi Sankyo JV submits NDA for candidate #shingles vaccine in Japan https://t.co/rtg3TBFhCh pic.twitter.com/VJ1D4woI6R

— Pharma Tech Focus (@PharmaTechFocus) April 21, 2017

Anglo-Japanese JV announces Shingrix submission in Japan https://t.co/97zsKYDTBA #pharma @GSK @DaiichiSankyo @DaiichiSankyoJP

— The Pharma Letter (@ThePharmaLetter) April 19, 2017

Our president & CEO, Dr. Robert Preti says “since becoming part of Hitachi Chemical over a year ago, we have seen increasing interest in leveraging our PCT Global Service Platform both in the United States and Japan.” Learn about our partnership with @GSK: https://t.co/aS6Tfc9yKr

— Minaris Regenerative Medicine (@MinarisRM) October 30, 2018

#WIPOReSearch Member companies Eisai, GSK, Johnson & Johnson, and Takeda featured in November Partnership Hub Snapshot. Advancing drug discovery around #NTDs, #malaria, and #tuberculosis. https://t.co/rtLTaYv0uA @Eisai_SDGs, @GSK, @JNJGlobalHealth, @TakedaPharma, @WIPO pic.twitter.com/mnm0AJo3Ai

— BVGH (@BIOVentures) November 12, 2019

Great news that Takeda has joined the Open Targets drug discovery initiative. More here: https://t.co/XOHP4TPSpX @targetvalidate @TakedaPharma @GSK @emblebi @biogen https://t.co/8SFnDO41B2

— Sanger Institute (@sangerinstitute) December 5, 2017

Takeda joins Open Targets drug discovery initiative. @targetvalidate @TakedaPharma @GSK @emblebi @biogen https://t.co/XOHP4TPSpX pic.twitter.com/qPW97LuHPW

— Sanger Institute (@sangerinstitute) December 5, 2017

Open Targets is 5 and we would like to thank all our 355 staff from our partners @biogen @celgene @emblebi @GSK @takeda @sanofi @sangerinstitute + guest institutions for contributing & being part of such successful #precompetitive community. Here's to many more years to come! pic.twitter.com/eiVhWWVlXx

— Open Targets (@targetvalidate) June 21, 2019

GlaxoSmithKline, Teva, Takeda Investing in Global Sustainability Performance with the Responsible Health Initiative https://t.co/IfCIxQ9AQu via @ecovadis @GSK @Teva @tevapharmeurope @TakedaPharma @CDCGreenHealthy @bbchealth @Healthcare @HCPolicy @healthjourno1 @HCnewsEU

— EnvironmentalPartner (@MonikaWojcik) January 10, 2019

The Dementia Discovery Fund first launched in 2015 with $100 million in capital from a range of Big Pharma companies, the U.K. government and the non-profit Alzheimer's Research UK @Biogen @GSK @Johnson&Johnson @Lilly @Pfizer @Takeda @ARUK @DHSCgovuk https://t.co/tdtENajGGx

— The Dementia Discovery Fund (@TheDDFund) August 9, 2018

236 preclinical pharma-academia #partnerships in 2015. @GSK at the top, followed by Bristol-Myers Squibb and Takeda https://t.co/ThlU1DygfF

— Giuseppe Recchia (@GGRecchia) March 26, 2016

In new best practice, 8 #pharma companies found by #AMRB2020 to have clinical-stage medicines that qualify as truly new – meaning they are more likely to remain effective for longer against resistant pathogens.https://t.co/ElTPlzfSRr @GSK @nabriva @Otsuka @scynexis @Summitplc pic.twitter.com/WtaCMcJTuA

— Access to Medicine Foundation (@AtMIndex) February 15, 2020

Did you hear? #JNJ is joining forces with @GatesFoundation, @Evotec, @GSK and Otsuka to develop a universal #TB treatment regimen. Learn how this unique collaboration builds on the #JNJ commitment to transform #TB treatment and #endTB for good ➡️ https://t.co/lJP54H0eGv pic.twitter.com/3TTCK3UHdu

— Johnson & Johnson Global Health (@JNJGlobalHealth) March 5, 2020

#WIPOReSearch Member companies Eisai, GSK, Johnson & Johnson, and Takeda featured in November Partnership Hub Snapshot. Advancing drug discovery around #NTDs, #malaria, and #tuberculosis. https://t.co/rtLTaYv0uA @Eisai_SDGs, @GSK, @JNJGlobalHealth, @TakedaPharma, @WIPO pic.twitter.com/mnm0AJo3Ai

— BVGH (@BIOVentures) November 12, 2019

On #WorldMosquitoDay, we want to thank our pharmaceutical partners for donating over seven billion life-changing treatments for #elephantiasis since 2012. #beatntds #endtheneglect @Eisai_SDGs @GSK pic.twitter.com/sYOaNgSfDE

— UnitingtoCombatNTDs (@CombatNTDs) August 20, 2020

Together with the Haitian Ministry of Health (MSPP) and our partners @GSK and @Eisai_SDGs, we are closer to eliminating a painful & disfiguring disease. #BeatNTDs

Learn more about our work in Hispaniola here: https://t.co/qFvEVXsITc pic.twitter.com/orZuiKoDGV

— The Carter Center (@CarterCenter) March 23, 2020

New #paediatric treatments recently launched for #HIV #soiltransmittedhelminths #epilepsy and #pneumonia from 4 companies detailed in #atmi2018 today: @GSK @JNJNews @Merck @eisai …. #worldChildrensDay2018 #WorldChildrensDay https://t.co/qnb3DoC0m1

— Danny Edwards (@dannyjedwards) November 20, 2018

A huge thank you to our Corporate Volunteers that have been coming in to help us with maintenance and gardening around the site. Thank you to Eisai, @NatWest_Help Bishop's Stortford, '@GivingMachineUK , @GSK and @Tesco it is greatly appreciated! pic.twitter.com/fxNrSocTeO

— St Elizabeth's Centre (@St_Elizabeths) July 17, 2018

On #WorldNTDDay we celebrate our industry partnerships to #beatNTDs including the innovative Drug Discovery Booster to discover new drugs with @abbvie @AstellasUS @AstraZeneca @bmsnews @Eisai_SDGs @merckgroup Shionogi & @TakedaPharma. pic.twitter.com/j4Xgs60vO2

— Drugs for Neglected Diseases initiative (@DNDi) January 30, 2020

#NTD supply chain at #Merck attended by #Eisai, @pfizer @GSK #MSD @JNJNews @DeutschePostDHL on #schistosomiasis pic.twitter.com/ViNezXdIKC

— Merck (@merckgroup) June 28, 2016

#BreakingNews for #investors and #media: First approval of daprodustat (Duvroq) received in Japan.

— GSK (@GSK) June 29, 2020

https://twitter.com/GSK/status/1275710004411187206
https://twitter.com/GSK/status/880055699820093440

We’re partnering with @GatesFoundation, @wellcometrust & govts from Germany, Japan & Norway to #outsmartepidemics: https://t.co/vBcq9Mjy8q pic.twitter.com/wLo1DQidw6

— GSK (@GSK) January 19, 2017

.@GSK's drug for anaemia caused by chronic kidney disease daprodustat has been approved in Japan, taking on a recently approved rival from Astellas https://t.co/FMPlzKUJ69

— pharmaphorum (@pharmaphorum) June 29, 2020

Chasing #Astellas and #Mitsubishi, #GSK files for Japanese approval of oral #anemia drug https://t.co/X7cihSiIXO @FierceBiotech @GSK #daprodustat

— Plexus Ventures (@PlexusVentures) August 22, 2019

.@GSK lands 1st approval for #Duvroq as Japan greenlights drug for renal anemiahttps://t.co/ZK5FYlDf8Z $GSK pic.twitter.com/Fg8sAlJhGa

— Market Intelligence: Healthcare (@SPGMIHealthcare) June 29, 2020

GSK receives regulatory approval for Duvroq (daprodustat) in Japan in anaemia due to chronic kidney disease https://t.co/bsks1Wrmvg @GSK More Asian life science business news at [LSA] at https://t.co/BOlw85yA1L pic.twitter.com/s4Y83zBEcQ

— [iito] Life Science (@iitoLifeScience) June 29, 2020

GSK/ViiV: Dovato (dolutegravir/lamivudine), once-daily, single-pill, 2-drug regimen for HIV-1, granted marketing approval by Japan Ministry of Health, Labour and Welfare https://t.co/GF5h5nwtqV @GSK @ViiVHC More Asian life science business news at [LSA] at https://t.co/o0PHiM2bwA

— [iito] Life Science (@iitoLifeScience) January 15, 2020

Check out new #DRG epidemiology data and forecast on #herpeszoster incorporating the new #vaccine trends of #shingrix across the United States, Western Europe and Japan – live now! @DRGinsights @GSK #Shingles #VaccinesSaveLives https://t.co/r92nrjfqvg https://t.co/8zvj8CWrfZ

— DRG Epidemiology (@DRG_Epi) February 21, 2019

To take the shot or not? #DRG epidemiology report forecasts over 400 million people eligible for #influenzavaccine in 2019 across the United States, Western Europe and Japan. Check out the detailed report @DRGinsights @GSK #flu #vaccinateforlife #fluseason #Influenza https://t.co/TkI62MgvXF

— DRG Epidemiology (@DRG_Epi) January 30, 2019

Japan approval for Darzalex and Benlysta https://t.co/lCa7sYMMr4 @Genmab @JanssenGlobal @GSK #pharma

— The Pharma Letter (@ThePharmaLetter) September 27, 2017

.@GSK #SHINGRIX containing $AGEN QS-21 Stimulon® received approvals in US, Canada, and now in Europe & Japan for #prevention of #shingles in adults >=50 [https://t.co/qfmmLw3SRf]; Details here [https://t.co/Lw9n7kRgI1]. QS-21 is a part of Agenus’ neoantigen vaccine #AutoSynVax.

— Agenus Inc. ($AGEN) (@Agenus_Bio) March 26, 2018

#Pharma with '#AI friendly' executives will prosper: US, Germany, and Japan-based companies lead the pack, says @DK_Analytics report // @DeepTech_VC

Read: https://t.co/Ra1FDwHAXE @Boehringer @GSK @LillyPad @Evotec @pfizer @Amgen @BayerPharma @Roche @Novartis @bmsnews @Merck pic.twitter.com/df32pzpwpr

— Outsourcing-Pharma (@OutsourcPharma) July 8, 2019

J&J, Sanofi and more look to ink national COVID-19 vaccine supply pacts in EU, Japan: reports | @AstraZeneca @JNJ @gatesfoundation @melindagates @BillGates @UniofOxford @BARDA @Sanofi @Moderna @Pfizer @BioNTech @Curevac @GSK #covid19 #vaccine #Biotech https://t.co/cRcjPrjCy9

— Aspen Biosciences (@aspenbio) July 19, 2020

On Monday, J. Sampson (@RobertWaltersJP), J. Spraggs (@GSK) and H. McLeish (@Japan_EY) kicked off the BCCJ's '#COVID19 Default to Action' webinar series.

Watch the full webinar, 'The Leadership Challenge', here: https://t.co/oix01kECMu pic.twitter.com/BhKaOagSdE

— British Chamber of Commerce in Japan (@BCCJapan) March 19, 2020

The nominees for the Diversity & Inclusion #2018BBAs are . . .
– @custommediakk
–@Freshfields Bruckhaus Deringer
– @GSK Japan
– @HoganLovells
-Intralink
– @LloydsofLondon Japan

Learn more about the nominees: https://t.co/KiQHd9dQX8 pic.twitter.com/ggzYLD8Qzk

— British Chamber of Commerce in Japan (@BCCJapan) October 30, 2018

Science and Technology 科学技術 Vol.12（pharmaceutical products 医薬品 Vol.5：influenza vaccines インフルエンザワクチン）

All the below links and excerpts are in English.

取り急ぎ標記関連リンクと当方作成の抜粋を以下のとおり貼っておきます。

Key Facts About Seasonal Flu Vaccine | @CDCgov

Flu Vaccination
How do flu vaccines work?
Flu vaccines cause antibodies to develop in the body about two weeks after vaccination. These antibodies provide protection against infection with the viruses that are used to make the vaccine.
The seasonal flu vaccine protects against the influenza viruses that research indicates will be most common during the upcoming season. Most flu vaccines in the United States protect against four different flu viruses (“quadrivalent”); an influenza A (H1N1) virus, an influenza A (H3N2) virus, and two influenza B viruses. There are also some flu vaccines that protect against three different flu viruses (“trivalent”); an influenza A (H1N1) virus, an influenza A (H3N2) virus, and one influenza B virus. Two of the trivalent vaccines are designed specifically for people 65 and older to create a stronger immune response.
What kinds of flu vaccines are available?
CDC recommends use of any licensed, age-appropriate influenza vaccine during the 2020-2021 influenza season, including inactivated influenza vaccine [IIV], recombinant influenza vaccine [RIV], or live attenuated influenza vaccine (LAIV). No preference is expressed for any influenza vaccine over another. Both trivalent (three-ingredient) and quadrivalent (four-ingredient) influenza vaccines will be available.
Quadrivalent flu vaccines include:
Standard-dose quadrivalent influenza shots that are manufactured using virus grown in eggs. These include Afluria Quadrivalent, Fluarix Quadrivalent, FluLaval Quadrivalent, and Fluzone Quadrivalent. Different influenza shots are licensed for different age groups. These four vaccines are approved for people 6 months of age and older. Most influenza shots are given in an arm muscle with a needle. One quadrivalent influenza shot (Afluria Quadrivalent) can be given either with a needle (for people aged 6 months and older) or with a jet injector (for people aged 18 through 64 years only). …
Are any of the available flu vaccines recommended over others?
…the Advisory Committee on Immunization Practices (ACIP) recommends…including inactivated influenza vaccine (IIV), recombinant influenza vaccine (RIV), or live attenuated nasal spray influenza vaccine (LAIV4)…
Who Should Not Be Vaccinated?
… Factors that can determine a person’s suitability for vaccination, or vaccination with a particular vaccine, include a person’s age, health (current and past) and any allergies to flu vaccine or its components. …
Flu and COVID-19
Does a flu vaccine increase your risk of getting COVID-19?
Vaccine Effectiveness
Can I get seasonal flu even though I got a flu vaccine this year?
What protection does a flu vaccine provide if I do get sick with flu?
Vaccine Benefits
What are the benefits of flu vaccination?
Vaccine Match
What if circulating viruses and the vaccine viruses are different?
Why is there sometimes not a good match between a vaccine virus and circulating viruses?
Flu viruses are constantly changing (called “antigenic drift”) ? they can change from one season to the next or they can even change within the course of one flu season. Experts must pick which viruses to include in the vaccine many months in advance in order for vaccine to be produced and delivered on time. …
… While all influenza viruses undergo changes when they are grown in eggs, changes in influenza A(H3N2) viruses are more likely to result in antigenic changes compared with changes in other influenza viruses. These so-called “egg-adapted changes” are present in most of the vaccine viruses recommended for use in egg-based vaccine production and may reduce their potential effectiveness against circulating influenza viruses. …
Vaccine Side Effects (What to Expect)
Can a flu vaccine give me flu?
No, a flu vaccine cannot cause flu illness. …
What side effects can occur after getting a flu vaccine?

Flu Vaccine (Flu Shot) | @MedicineNet
Facts you should know about the influenza vaccine (flu shot)
・Types of influenza (flu) vaccines include the injection (killed virus), recombinant (made without flu virus), and nasal spray vaccines (containing live virus). …
What is influenza (flu)?
… Flu is a respiratory infection, that is, an infection that develops primarily in the lungs. People often call respiratory infections caused by other viruses the flu, but this is incorrect. These other infections are usually categorized as URIs (upper respiratory infections) and have multiple causes. …
Influenza viruses are divided scientifically into three types, designated A, B, and C. Influenza types A and B are responsible for epidemics of respiratory illness that occur almost every winter. Influenza type C usually causes either a very mild respiratory illness or no symptoms at all; it does not cause epidemics and does not have the severe public health impact of influenza types A and B. Type A viruses are divided into subtypes and are named based on differences in two viral surface proteins called hemagglutinin (H) and neuraminidase (N). There are 16 known H subtypes and nine known N subtypes. …
The so-called swine flu pandemic of 2009 was caused by a novel influenza A virus designated H1N1 based upon its surface protein types. This virus was originally referred to as swine flu because many of the genes in this new virus were very similar to influenza viruses that normally occur in pigs in North America. However, this virus was actually quite different from the typical swine flu viruses found in pigs.

Types of seasonal influenza vaccine | @WHO_Europe
Two types of influenza vaccine are widely available: inactivated influenza vaccines (IIV) and live attenuated influenza vaccines (LAIV). Traditionally, influenza vaccines (both IIV and LAIV) have been produced to protect against 3 different seasonal influenza viruses (also called trivalent vaccines). In most countries this is still the case and the current trivalent vaccines contain influenza A(H3N2), pandemic A(H1N1) and 1 of 2 influenza B lineage viruses. However, recently vaccines which protect against 4 different viruses, including both influenza B lineage viruses (quadrivalent vaccines), have become available in some countries. …
Annual selection of viruses
The composition of influenza vaccines (both IIV and LAIV) are updated annually by WHO based on information gathered from the Global Influenza Surveillance and Response System (GISRS)…

Flu vaccine | @NHSuk
Flu vaccine and coronavirus (COVID-19)
Flu vaccination is important because:
・if you’re at higher risk from coronavirus, you’re also more at risk of problems from flu
・if you get flu and coronavirus at the same time, research shows you’re more likely to be seriously ill
・it’ll help to reduce pressure on the NHS and social care staff who may be dealing with coronavirus
If you’ve had COVID-19, it’s safe to have the flu vaccine. It’ll be effective at helping to prevent flu.

Influenza Vaccine for the 2020-2021 Season | @US_FDA
Influenza Vaccine (Flu Shot and Nasal Spray) for Adults | @WebMD
Q&A on Influenza (English; 11/21/2019) | 厚生労働省

Science and Technology 科学技術 Vol.11 ／ #Coronavirus #コロナウイルス Vol.13（pharmaceutical products 医薬品 Vol.4：drugs 治療薬）

All the below links and excerpts are in English.

リンクと当方作成の抜粋を取り急ぎ以下のとおり貼っておきます。

COVID-19 (coronavirus) drugs: Are there any that work? | @MayoClinic
… Remdesivir …
・Antiviral drugs. In addition to remdesivir, other antiviral drugs being tested include favipiravir and merimepodib. …
・Dexamethasone. …reduces the risk for deaths by about 30% for people on ventilators and by about 20% for people who needed supplemental oxygen. … Other corticosteroids, such as prednisone, methylprednisolone or hydrocortisone, may be used if dexamethasone isn’t available. However, their effectiveness isn’t yet known. …
・Anti-inflammatory therapy. …
・Immune-based therapy. … Convalescent plasma is blood donated by people who’ve recovered from COVID-19. …mesenchymal stem cells and monoclonal antibodies.
・… Researchers study amlodipine and losartan. But it’s not yet…
・Hydroxychloroquine and chloroquine. These malaria drugs… the FDA withdrew that authorization…
・Drugs to prevent COVID-19. …

The Latest Research on COVID-19 Treatments and Medications in the Pipeline (10/23/2020) | @GoodRx
Commonly used treatments for COVID-19 and therapies with emergency use authorizations (EUAs)
・Remdesivir (Veklury)
・Dexamethasone
・Convalescent plasma
New treatments in early phase studies
・Monoclonal antibodies (MABs) … Regeneron and Eli Lilly are two companies that both have MABs in development for COVID-19, currently called REGN-COV2 and LY-CoV555, respectively. …
Treatments that the NIH recommend against using for COVID-19
・Hydroxychloroquine and chloroquine
・Azithromycin … One research group looked at azithromycin in combination with hydroxychloroquine for COVID-19. They reported that 93% of patients cleared the virus after 8 days, but there was no control group so we don’t know if people would have cleared the virus on their own without the medications. There are concerns about potentially serious side effects when using azithromycin and hydroxychloroquine together. The NIH currently recommends against using azithromycin for COVID-19.
・Tocilizumab (Actemra) and other IL-6 inhibitors … By blocking IL-6, tocilizumab helps to calm down the immune system and is believed to also help with managing cytokine storms.
Research on tocilizumab started with a study from France, which reported that people who got tocilizumab were less likely to require ventilation or die. Another study from Italy found that those who got tocilizumab had a lower death rate, though about the same percentage of patients from both groups needed ventilators. On the other hand, tocilizumab did not help COVID-19 patients with early-stage pneumonia. A phase 3 study from the manufacturer also found that tocilizumab did not help for hospitalized COVID-19 patients with severe pneumonia. …
… They showed that patients with severe symptoms who got Kevzara did worse compared to placebo, but patients who had even more severe (critical) symptoms improved compared to placebo. …
・Kinase inhibitors … acalabrutinib (Calquence); baricitinib (Olumiant); ruxolitinib (Jakafi); tofacitinib (Xeljanz) …
・Interferons
・Kaletra (lopinavir/ritonavir)
・Ivermectin
Repurposed medications with minimal COVID-19 data
・Tamiflu (oseltamivir)
・Avigan (favipiravir) and other antiviral medications … In vitro studies have shown that high doses of favipiravir were able to prevent human cells from being infected with SARS-CoV-2. …
・Colcrys (colchicine)

Coronavirus Drug and Treatment Tracker (10/29/2020) | @nytimes

Blocking the Virus – Antivirals can stop viruses such as H.I.V. and hepatitis C from hijacking our cells. …
・Remdesivir
・Favipiravir
・Molnupiravir
・Recombinant ACE-2
・Ivermectin
・Oleandrin
・Lopinavir and ritonavir
・Hydroxychloroquine and chloroquine
Mimicking the Immune System -… Drugs might help people who can’t mount an adequate defense.
・Convalescent plasma
・Monoclonal antibodies
・Interferons
Putting Out Friendly Fire – The most severe symptoms of Covid-19 are the result of the immune system’s overreaction to the virus. …
・Dexamethasone and Other Corticosteroids
・Cytokine Inhibitors
・Blood filtration systems
・Stem cells
Other Treatments …
Pseudoscience and Fraud …

Treatments for COVID-19: What helps, what doesn’t, and what’s in the pipeline (10/23/2020) | @HarvardHealth

U.S.A. アメリカ Vol.124（Maryland メリーランド州 Vol.2: pharmaceutical corporations 製薬会社）

All the below link and tweets are in English.

取り急ぎ以下貼っておきます。

Maryland Vol.9 (corporations: Novavax)

上記リンク内に無い本日までのツイート

This morning, we provided an update related to Phase 3 development of our #COVID-19 #vaccine candidate. We are pleased to share that our pivotal Please 3 trial in the UK is being expanded to 15,000 volunteers. Please read our news release here: https://t.co/d2KVr0KAvo $NVAX pic.twitter.com/mEiO5x2PRK

— Novavax (@Novavax) October 27, 2020

Novavax delays U.S. trial of COVID-19 vaccine candidate to November https://t.co/CwpxuwnHhC pic.twitter.com/tlsawilQnx

— Reuters (@Reuters) October 27, 2020

Covid-19 vaccine: Novavax delays US clinical trials to Novemberhttps://t.co/R6MhC6NVjf pic.twitter.com/I7wdk2F9Jk

— Mint (@livemint) October 27, 2020

Data from an early-to-mid stage trial of the vaccine is expected on Friday, the company said. Earlier data had shown the vaccine produced high levels of antibodies against the novel coronavirus.#covid19 #coronavirusvaccine #UStrial #novavax
https://t.co/dXEIk7KCic

— CNBC-TV18 (@CNBCTV18News) October 28, 2020

Novavax delays US trial of COVID-19 vaccine candidate to November https://t.co/YMGnO6n8up

— The Tribune (@thetribunechd) October 27, 2020

Novavax Delays US Trial Of #COVID19Vaccine Candidate To November https://t.co/5PSEM9QpfV pic.twitter.com/TRk8t7SHa0

— NDTV (@ndtv) October 27, 2020

Novavax expects its U.S. Phase Three clinical trial to begin by the end of November. https://t.co/Al3X0QYcLR

— WJZ | CBS Baltimore (@wjz) October 27, 2020

$NVAX Novavax Shares Jump After Coronavirus Vaccine Trial Updatehttps://t.co/axH7XPkjWq

— Top Stock Alerts (@TopStockAlerts1) October 27, 2020

FREE TO READ | CORONAVIRUS BLOG
— Novavax's U.S. vaccine trial won't start until November
— India sees lull in new cases
— No pub crawls, Japanese governor sayshttps://t.co/EIthN9I75m

— Nikkei Asia (@NikkeiAsia) October 27, 2020

Novavax delays U.S. trial of Covid-19 vaccine candidate to November $NVAX $PFE $AZN-GB https://t.co/VWVLoKSnij

— Healthcare News (@HealthcareBeat) October 27, 2020

$NVAX Novavax expands late-stage UK trial for COVID-19 vaccine candidate to 15,000 volunteers https://t.co/kITh9ocOz3 via @proactive_UK #NVAX

— Ruth Gemmell (@ruth_proactive) October 27, 2020

Covid vaccine, Novavax, delay rumours, weighing on sentiment By @ross_burland https://t.co/yJjp4PgX8b #Coronavirus #Equities #Politics

— FXStreet News (@FXstreetNews) October 26, 2020

An alphabet soup of potential COVID-19 vaccines presented by Dr Gerald Evans, Chair ID ⁦⁦@QueensuDOM⁩ ⁦@KingstonHSC⁩. Several in phase 3-Astra Zeneca, Can-Sci, Pfizer, Moderna & Novavax- stimulate neutralizing antibodies at levels like those in convalescent serum pic.twitter.com/LKwZ4xikJ8

— Stephen L. Archer (@DrStephenArcher) October 27, 2020

All ready for our last #novavax vaccine trial day – almost 500 fantastic volunteers have been vaccinated. Awesome team ⁦@CityOfResearch⁩ ⁦@SaralayaD⁩ ⁦@BTHFT⁩ ⁦@BiBresearch⁩ pic.twitter.com/XoGoOZvCul

— John Wright (@docjohnwright) October 26, 2020

I’m in the phase 3 Novavax vaccine study and so far it’s been relatively painless (blood testing, injection, covid swab etc). They need more volunteers from a range of demographics to test its effectiveness and immune responses. Register here if you can: https://t.co/362g21Z2Zv pic.twitter.com/6d8BxTDci0

— Sarah Jankowitz (@SarahJankowitz) October 26, 2020

Earlier today, I got a shot as part of the Novavax Covid-19 vaccine trial (phase 3). Been more than an hour and I feel fine. In three weeks, I'll get a second shot.

Many thanks to @RoyalFreeNHS & @iit_ucl.

You too can be a part of helping science. https://t.co/Uoii7jJLvr

— Akshat Rathi (@AkshatRathi) October 23, 2020

We are proud that @Keele_CTU is supporting the @NIHRresearch regional site in a study to test the effectiveness of the Novavax Covid-19 vaccine candidate ⬇️ https://t.co/O7AnznKGW6

— Keele University (@KeeleUniversity) October 22, 2020

COVID-19 Vaccine updates:
– Pfizer and Moderna in Phase 3 trials; they may be ready to apply for emergency FDA authorization in late November.
– Johnson & Johnson on pause. Astrazeneca on FDA hold.
– Novavax to start Phase 3 as soon as this month. pic.twitter.com/b2lyWDHUAM

— Randz (@RH4N6) October 21, 2020

An extraordinary structural, biophysical, and antigenic characterization of the @novavax vaccine spike protein and glycanshttps://t.co/3qeRtUNJuX
Just published @ScienceMagazine
Proud of @Sandhyareddy88 and my @scrippsresearch colleagues who did this work pic.twitter.com/e5UBuw0zE5

— Eric Topol (@EricTopol) October 20, 2020

high hopes for the novavax subunit vaccine. Nice cryo-EM work from my @WardLab1 colleagues. https://t.co/gqUklJHLzE

— ZackB (@zacharyberndsen) October 20, 2020

awesome stuff, I'm on the novavax phase 3 trials that just started in uk. got my first shot last week.

— chipped (@chipped1) October 19, 2020

World leading research: NIHR's new National Patient Recruitment Centres (NPRCs) are playing a leading role in delivering #Covid19 vaccine research, with the world's first participant to join the @Novavax phase 3 vaccine trial recruited at Blackpool NPRC https://t.co/seAwKjXsNp pic.twitter.com/o6rWgzIXUr

— NIHR Research (@NIHRresearch) October 19, 2020

$NVAX Novavax. Currently in Previous Month Low Pivot range. 85 area of confluence for both Monthly S1 floor Pivot and Monthly Camarilla L4. Could be a potential reversal area to keep an eye on. pic.twitter.com/FhpGrTUKkE

— Pivot Investor (@pivotinvestor) October 27, 2020

$NVAX Novavax's stock rises 3% as it announces plans to share Phase 2 vaccine data this week https://t.co/44CU9SwBDn

— Biomed & Tech Stock Focus (@MarcJacksonLA) October 27, 2020

Novavax's stock rises 3% as it announces plans to share Phase 2 vaccine data this week https://t.co/lanQONwG2A

— MarketsTicker (@MarketsTicker) October 27, 2020

The Research Team at @NTHFTResearch are still recruiting to the NOVAVAX Vaccine Study at Hartlepool Hospital

If you meet the criteria, & want to help find a #COVID19 vaccine, enrol using the link below and book an appointment as soon as next week#BePartOfResearch #ResearchNENC https://t.co/CuKSQURDxZ

— NIHR CRN North East and North Cumbria (@NIHRCRN_NENCumb) October 22, 2020

$NVAX Novavax call volume above normal and directionally bullish pic.twitter.com/mIrEZDlVfL

— Maria Chaudhry (@mchaudhry82) October 20, 2020

Novavax $NVAX makes vaccines by sticking proteins onto microscopic particles; their flu vaccine finished Phase 3 trials in March. The company launched trials for a Covid-19 vaccine in May, in July the U.S. government awarded $1.6 billion to support the vaccine’s clinical trials. https://t.co/7wiLh1aGbA

— artificial mustaches (@artmustaches) October 20, 2020

ツイッター検索で上記製薬会社名及び Japan や日本の5製薬会社各社名を入れて出て来たもの

Japan in deals with AstraZeneca, Novavax for COVID-19 vaccines https://t.co/ZES9ZrOmIz pic.twitter.com/0dUg7UjM6Z

— Reuters (@Reuters) August 7, 2020

https://twitter.com/Reuters/status/1291764717330071557

Japan in deals with AstraZeneca, Novavax for Covid-19 vaccines https://t.co/32k1B24nye

— The Straits Times (@STcom) August 7, 2020

Covid-19 roundup: Novavax inks vaccine deals with Japan and India; AstraZeneca nearing agreements with Japan and Brazil https://t.co/1Gnd5TUZMe

— Endpoints News (@endpts) August 7, 2020

Novavax taps Japan's AGC to make ingredient in COVID-19 shot https://t.co/Drdp3TuRB7 #coronavirus #vaccine #pharma $NVAX

— Nikkei Asia (@NikkeiAsia) June 4, 2020

Japan is very selective. Why did they choose Novavax and their Sars-CoV-2 candidate? https://t.co/BGWVmtFIyQ

— Jeffrey A. Hirschfield, MD, DipABLM (@DrHirschfield) August 11, 2020

$Nvax Novavax Inks Vaccine Deals In Japan, India; Analyst Sees 70% Stock Upside
Follow us @WebullGlobal
https://t.co/AYixzJLFgR

— Kyrell Fontaine (@KkFontaine23) August 10, 2020

Novavax Inks Vaccine Deals In Japan, India; Analyst Sees 70% Stock Upsidehttps://t.co/OufJCpbrW6 $NVAX $TAK

— TipRanks (@TipRanks) August 9, 2020

Japan in deals with AstraZeneca, Novavax for COVID-19 vaccines https://t.co/jnSEVdnzRX

— SpeedyRalph (@RalphSpeedy) August 9, 2020

Fujifilm to supply Novavax with key part of COVID vaccine https://t.co/ki25NgUjXZ #IndoPacific #Fujifilm #Novavax #COVID19 #Vaccine #Japan

— Indo-Pacific Defense FORUM (@IPDefenseForum) July 24, 2020

$NVAX is pleased to announce a partnership with global vaccine leader @Takeda to develop, manufacture & commercialize our #COVID19 vaccine candidate, #NVXCoV2373, in Japan. To learn more, please read today's announcement here: https://t.co/QhbV2LVUBC pic.twitter.com/iSDc9EraHp

— Novavax (@Novavax) August 7, 2020

As a global pharmaceutical company it is our responsibility to support efforts to help protect people from #COVID19. This is why our partnership with @Novavax on their COVID-19 vaccine candidate in Japan is so important to us. Read more here: https://t.co/nl4FCxrlkC pic.twitter.com/AoU8AFRe4e

— Takeda (@TakedaPharma) August 10, 2020

Today, we announced a collaboration with @Novavax for the development, manufacturing and commercialization of the company's #COVID19 #vaccine candidate in Japan. Read the full release here: https://t.co/P6k0JYLAkx pic.twitter.com/cmPVlaJ30V

— Takeda (@TakedaPharma) August 7, 2020

Takeda to make Novavax's COVID-19 vaccine candidate in Japan https://t.co/1AFganqthk pic.twitter.com/L99scxnKI8

— Reuters Business (@ReutersBiz) August 7, 2020

Takeda to make Novavax's COVID-19 vaccine candidate in Japan https://t.co/v99Uu2hR2s pic.twitter.com/SlYBoO5ap4

— Reuters (@Reuters) August 7, 2020

Pharmaceutical giant @TakedaPharma will help startup @Novavax commercialize its #COVID19 vaccine in Japan. The drugmaker anticipates manufacturing 250 million doses per year and the first batches of the vaccine will be ready in 2021 https://t.co/0EKQ7NCAMD

— MassEcon (@MassEcon) August 18, 2020

Takeda collaborates with #Novavax for COVID 19 vaccine in Japan. Read More: https://t.co/cqNwwjGRx8

— investmedical (@investmedical) August 17, 2020

8-13-2020: In Japan, the Novavax/Fujifilm vaccine will be made by Takeda. In South Korea, the Novavax/Fujifilm vaccine will be made by SK Bioscience:https://t.co/ndgoO19YTt https://t.co/N3l2kzeesS https://t.co/9gYAMfHPYK https://t.co/M0ig6pMvrU https://t.co/eqCJzUBYSq

— Ronald M. Chavin (@rmchavin) August 13, 2020

Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japanhttps://t.co/CdDsBOTJzl #news #pharma #pharmiweb

— Pharma News (@pharminews) August 13, 2020

Takeda and Novavax are partnering on manufacturing COVID‑19 vaccine candidate https://t.co/e6AHf5G2SL via @GMP news #coronavirus #vaccine #COVID19 #Takeda #GMPNews

— GMPnews.Net (@GMPnewsNet) August 10, 2020

Novavax announces a deal with Takeda to manufacture and distribute its #COVID19 vaccine in Japan. The Phase 3 trial of the vaccine is expected to begin this fall. $NVAX $TAK https://t.co/NmTzfxt0aF

— Microbial Biotech News (@MicrobialNews) August 9, 2020

Novavax Partners With Takeda to Sell Its Coronavirus Vaccine in Japan https://t.co/q6uz9o0ux2

— cafepharma (@cafepharma) August 9, 2020

Takeda strikes deal to bring Novavax' NVX‑CoV2373 COVID-19 vaccine to Japan #Takeda #Novavax #Japan #Covid-19 #coranavirus #NVX‑CoV2373 #pharmanews #vaccine https://t.co/o36Js4vWHc

— OyeCricket.com (@cricket_fundas) August 8, 2020

#NVAX Novavax Partners With Takeda for Japan Output of Covid Drug https://t.co/Wx0HRgz0C2

— Emanuele Orsili (@emanueleorsili) August 7, 2020

Takeda Pharmaceutical Co. said Friday it will produce and sell in Japan a COVID-19 vaccine being developed by U.S. biotechnology firm Novavax Inc.https://t.co/xXoi1wqU4u

— Jeffs (@jeffs_araujo35) August 7, 2020

@TakedaPharma to supply @Novavax's #coronavirus vaccine candidate in Japan https://t.co/utm8bO9xNW pic.twitter.com/qWtykeLinR

— BioBuzz (@BioBuzzMaryland) August 7, 2020

#Vaccine Data From @Novavax

These look like strong results:
– the antibody levels for the adjuvant groups were at least 100x over the non-adjuvant ones
– neutralizing antibodies were 4x those seen in #COVID19 convalescent serumhttps://t.co/jY54SR1EBl

— EPIDATUM (@epidatum) August 7, 2020

Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan! Government of Japan to provide funding to Takeda for tech transfer and scale-up of manufacturing! $NVAX $TAK #COVID19 #coronavirus #vaccine https://t.co/91240ADASi pic.twitter.com/sjAs5FCdT2

— AlphaBronze (@Alpha_Bronze) August 7, 2020

$NVAX and Takeda Announce Collaboration for Novavax’ #COVID19 Vaccine Candidate in Japan. $TAK https://t.co/zpCtBMl2sK

— Bio Stocks™ (@BioStocks) August 7, 2020

The Latest Info On Pharmaceutical Treatments And #Vaccines•#GileadSciences•#AbbVie•#Moderna•Johnson&Johnson•#EliLilly•#Pfizer•#GlaxoSmithKline•#VirBiotechnology•#Sanofi•Apeiron Biologics•#CureVac•#Dyadic•#Mesoblast•#Novavax•#Roche•#Takeda https://t.co/De0VjosMjf

— LebensKünstler (@GmmLhDBsc2heyst) March 20, 2020

U.S. Flu Vaccine Market @SanofiPasteur, @gsk, @Seqirus, @CSLLimited, @AstraZeneca, @Mylan, @BioDiem, @Novavax, @BiondVax, @Medicago, @Moderna, @Pneumagen, @Daiichi–Sankyo, @Altimmune, @FluGen, @Imutex #flu https://t.co/Bd1Cnao6Hb via @dpiresearch

— DPI Research (@DPIResearch) October 5, 2020

United States Influenza Vaccines Market 2018-2025 Analysis by emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi TanabePharma and Biondvax Pharmaceuticals Ltd, Seqirus, Sanofi Pasteur, GlaxoSmithKline (GSK) and AstraZeneca https://t.co/qQqrKL10Fm via @openPR

— DPI Research_Vaccine (@MarketR_Vaccine) November 5, 2018

United States Shingles Vaccine Market https://t.co/SiApsaGBM1 @SanofiPasteur,@GSK,@Seqirus,@CSL Limited,@AstraZeneca,@Mylan,@GammaVaccines,@Hualan,@ShanghaiInstitute,@BioDiem,@Novavax,@BiondVax,@Medicago,@Moderna,@Pneumagen,@Daiichi–Sankyo,@Altimmune,@FluGen,@Imutex

— DPI Research Official (@dpi_research) September 2, 2020

World 世界情勢等 Vol.7

All the below links are in English.

取り急ぎ以下貼っておきます。

World Vol.51
World Vol.50
World Vol.49
World Vol.48
World Vol.47
World Vol.46
World Vol.45
World Vol.44
World Vol.43
World Vol.42
World Vol.41

Science and Technology 科学技術 Vol.10 ／ #Coronavirus #コロナウイルス Vol.12（pharmaceutical products 医薬品 Vol.3：vaccines ワクチン）

All the below links and excerpts are in English.

標記関連リンクと当方作成の一部抜粋を取り急ぎ以下のとおり貼っておきます。
(The below Vaccine Tracker is from @nytimes.)

Coronavirus Vaccine Tracker (10/24/2020) | @nytimes
〇　Genetic Vaccines – Vaccines that deliver…coronavirus’s own genes into our cells to provoke an immune response.
• Moderna & National Institutes of Health [PHASE 3] mRNA
…planned to wait until a significant number of volunteers became sick with Covid-19 and then see how many had been vaccinated. It may take till the end of 2020 or early 2021 to reach the necessary numbers.
• BioNTech & Pfizer & Fosun Pharma (China) [PHASE 2 & 3] mRNA
… Pfizer and BioNTech would not apply for an emergency use authorization before late November at the earliest. …
…will have to be chilled to minus 80 degrees Celsius (minus 112 degrees Fahrenheit) until it’s ready to be injected.
• Zydus Cadila (India) [PHASE 2] DNA-based
• CureVac (Germany) [PHASE 2] mRNA
• Imperial College London (UK) & Morningside Ventures (UK) [PHASE 1 & 2] “self-amplifying” RNA
• AnGes (Japan) & Osaka University (Japan) & Takara Bio (Japan) [PHASE 1 & 2] DNA-based
• Arcturus Therapeutics (CA) & Duke-NUS Medical School (Singapore) [PHASE 1 & 2] mRNA
• Inovio (PA) [PHASE 1] DNA-based
• Genexine (South Korea) [PHASE 1] DNA-based
• Academy of Military Medical Sciences (China) & Suzhou Abogen Biosciences (China) & Walvax Biotechnology (China) [PHASE 1] mRNA-based
• Chulalongkorn University (Thailand) & Chula Vaccine Research Center (Thailand) [PHASE 1] mRNA-based
• Entos Pharmaceuticals (Canada) [PHASE 1] DNA
• Sanofi (France) & Translate Bio (MA) [PRECLINICAL] mRNA
…
〇　Viral Vector Vaccines – Vaccines that contain viruses engineered to carry coronavirus genes. …
• CanSino Biologics (China) & Academy of Military Medical Sciences (China) [PHASE 3]
• Gamaleya Research Institute (Russia) [PHASE 3]
• Johnson&Johnson & Beth Israel Deaconess Medical Center (MA) [PHASE 3]
• AstraZeneca & University of Oxford [PHASE 2 & 3]
ReiThera (Italy) & Lazzaro Spallanzani National Institute for Infectious Diseases (Italy)；Vaxart (CA)；Merck & Themis Bioscience (Austria) & Institut Pasteur (France)；German Center for Infection Research (Germany)；Merck & IAVI (NY)；ImmunityBio (CA)；Novartis …
〇　Protein-Based Vaccines – Vaccines that contain coronavirus proteins but no genetic material. …
• Novavax [PHASE 3]
• Anhui Zhifei Longcom (China) & Chinese Academy of Medical Sciences (China) [PHASE 2]
Finlay Vaccine Institute (Cuba)；Vector Institute (Russia)；Sanofi & GSK、SpyBiotech (UK)；Clover Biopharmaceuticals (China) & GSK & Dynavax (CA)； University of Queensland (Australia) & CSL (Australia)；Medicago (Canada) & GSK & Dynavax；Vaxine (Australia)；Kentucky BioProcessing (KY)；Medigen (Taiwan) & Dynavax；Adimmune (Taiwan)；COVAXX (NY) …
〇　Inactivated or Attenuated Coronavirus Vaccines – Vaccines created from weakened coronaviruses…
• Wuhan Institute of Biological Products (China) [PHASE 3]
• Sinopharm (China) [PHASE 3]
• Sinovac Biotech (China) [PHASE 3]
• Indian Council of Medical Research (India) & National Institute of Virology (India) & Bharat Biotech (India) [PHASE 3]
…..

Johnson & Johnson, AstraZeneca coronavirus vaccine trials set to resume: Investigators found the unexplained illnesses in both trials appeared unconnected to the vaccines (10/24/2020) | @washingtonpost
… In the Johnson & Johnson trial, which was paused on Oct. 12, a man who received a vaccination suffered a stroke that may have been triggered by an infection. To conclude it was not likely to be related to the shot, investigators probed not only the medical details of the event, but also examined a safety database of 100,000 people who have received vaccines that use the same underlying technology. …
… The company is testing the only vaccine that aims to protect people with a single shot; other prospective vaccines require a return visit and second shot three to four weeks after the first to trigger a protective immune response.
It was the second late-stage vaccine trial put on hold in recent weeks; the vaccine being developed by AstraZeneca and the University of Oxford was halted on Sept. 6 after a British participant developed a neurological problem. …
… Carlos del Rio, an infectious diseases physician at Emory University School of Medicine. “As long as the data and safety monitoring board has reviewed the data and says its OK to proceed, we proceed.”
… William Hartman, a principal investigator of the AstraZeneca trial at the University of Wisconsin Hospital and Clinics. “It is too soon to tell whether participant enthusiasm will approach what it was prior to the pause. …

Covid: More coronavirus vaccine trials in Wales ‘within weeks’ (24/10/2020) | @BBC

Rush for results could lead to inferior Covid vaccine, say scientists (25/10/2020) | @guardian

Dozens of COVID-19 vaccines are in development. Here are the ones to follow. : Here are the COVID-19 vaccine prospects that have made it to phase three trials and beyond. (10/13/2020) | @NatGeo
• Novavax (MD) NVX-CoV2373
• Johnson & Johnson (NJ) JNJ-78436735
• Moderna Therapeutics (MA) mRNA-1273
• Pfizer (NY) & BioNTech (Germany) BNT162b2
• University of Oxford (UK) & AstraZeneca (UK) ChAdOx1 nCoV-19
• Sinovac (China) & Butantan (Brazil) CoronaVac
• Sinopharm (China) & Wuhan Institute of Biological Products (China) None
• Murdoch Children’s Research Institute (Australia) & University of Melbourne (Australia) Bacillus Calmette-Guerin BRACE trial
• CanSino Biologics (China) Ad5-nCoV
• The Gamaleya National Center of Epidemiology and Microbiology (Russia) Sputnik V

U.S.A. アメリカ Vol.123（New Jersey ニュージャージー州 Vol.4: pharmaceutical corporations 製薬会社）

All the below link and tweets are in English.

Vol.122 (New Jersey ニュージャージー州 Vol.3: pharmaceutical corporations 製薬会社）の続き

ツイッター検索で上記製薬会社名及び Japan や日本の5製薬会社各社名を入れて出て来たもの

Japan's PeptiDream to work with Merck in developing COVID-19 therapies https://t.co/GzIqX0LbZQ pic.twitter.com/T8MxO4ZuZu

— Reuters (@Reuters) June 12, 2020

CDC Director Brenda Fitzgerald bought stock in Japan Tobacco, Merck and Humana– *AFTER* she became the nation's top public health official.

The investigation from @SarahKarlin
& @Briannaehley: https://t.co/gHNHqOP8IG

— Adam Cancryn (@adamcancryn) January 30, 2018

During COVID, the growing dangers and threat posed by antibiotic-resistant bacteria outweigh the global level of preparedness. Meanwhile, antibiotic R&D is suffering for investment. Forge applauds @Merck and Kyorin for supporting @PewCharitableTrust https://t.co/i0ToNjccgt

— Forge Therapeutics (@ForgeThera) October 23, 2020

New data from Merck, Kyorin shared to Pew's SPARK @pewtrusts @Merck https://t.co/ibg9R6JXFn

— The Science Advisory Board (@ScienceBoard) October 21, 2020

“Our hope is that the data from @Merck’s research will help catalyze discovery of new #antibiotics for Gram-negative pathogens,” @pewhealth’s @KathrynTalking says of the pharmaceutical company’s recent data contribution to SPARK. https://t.co/qd6oOf3y15

— Save Antibiotics (@saveantibiotics) October 21, 2020

Japan Prize / Merck-Banyu Lectureship for Naoya Kumagai / DECHEMA Prize for Timothy Noeel (News) https://t.co/npKfaLlQBg pic.twitter.com/6Q1xQyXK11

— Angewandte Chemie (@angew_chem) April 26, 2018

@MSD_JAPAN

In today's News Briefing: Two years unveiling a flop in their first PhIII trial of guadecitabine as a frontline treatment, Otsuka is back with 2 more pivotal setbacks. And the #FDA approved an expanded indication for Merck’s best-seller Keytruda. https://t.co/5svHdzG7UG

— Endpoints News (@endpts) October 16, 2020

Merck adds to lung cancer wall with Otsuka deal https://t.co/l9RW0Njibg pic.twitter.com/GnYs2TWMeI

— HealthIT and Biotech (@UCCharting) January 9, 2020

Merck adds to lung cancer wall with Otsuka deal | BioPharma Dive https://t.co/k063lZ3W8E

— Mr. Brian Uberig (@Brian_Uberig) January 8, 2020

MSD enlists Otsuka units Taiho and Astex to develop KRAS therapies https://t.co/2QOB4obxMj #pharma #healthcare

— PharmaTimes (@PharmaTimes) January 8, 2020

Merck and Otsuka enter into a research and development pact for a drug that targets a dangerous subset of cancers https://t.co/8ESVh069oT

— Bloomberg (@business) January 7, 2020

Merck & Co. partners with Otsuka units Taiho, Astex on cancer drug development https://t.co/qu7yCDMN5P $MRK $ASTX

— FirstWord Pharma (@fwpharma) January 6, 2020

Industry Insight of Oncolytic Virus Market Research Segment, In-depth Analysis | Merck, Otsuka Pharmaceutical Co, Pfizerhttps://t.co/lnfmzWgTWA #news #pharma #pharmiweb

— Pharma News (@pharminews) December 24, 2019

Oncolytic Virus Market Analysis and Reviews 2019 to 2025 | Merck, Otsuka Pharmaceutical Co, Pfizer, Roche, Cold Genesys, Genelux https://t.co/5MnJLhS6t2 pic.twitter.com/4THnWUqxql

— Science Examiner (@ScienceExaminer) October 7, 2019

Analyst Keshalini Sabaratnam @Pharma_GD on the #sales #forecast for @Merck and #Otsuka 's #Keytruda (pembrolizumab) projected to be top drug by 2023 and what does this mean for their #contractmanufacturers #CDMO #CMO @AstraZeneca @BoehringerDE https://t.co/R6Wmwcm2Qb

— GlobalData PharmSource (@PharmSource) October 2, 2019

The $200 discount for the Marketing Disruption Summit ends Friday! Explore the full agenda and get your tickets here: https://t.co/sueo5mBZEd #sanofi #BMS #ferring #boehringeringelheim #merck #teva #gsk #abbvie #astrazeneca #pfizer #bayer #otsuka #us #pharma #marketing #data #it pic.twitter.com/u9P8j4mLcn

— Reuters Events Pharma (@RE_Pharma) August 14, 2019

Otsuka buying Waltham, Mass.-based antibody specialist Visterra for $430 million, all-cash. https://t.co/FIwi2S4VeB

Last valuation was $188 million, per Pitchbook. Omega, Alexandria, Cycad Group, Gates Foundation, Merck, Vertex, Temasek, Alexandria among investors.

— Matthew Herper (@matthewherper) July 11, 2018

"Editor’s note: The author did not initially disclose having received payments from Boehringer Ingelheim, Eli Lilly, Hoffmann-La Roche, Lundbeck, Merck, Sharpe, and Dohme, Otsuka, Pfizer, and other companies." You have to ask – why the delay? @AmerGeriatrics https://t.co/RWpZYRJ7zK

— James Richardson, MD, MPH (@DocRock54) March 10, 2018

Merck and Otsuka US agree: Misalignment in healthcare is our biggest cha… https://t.co/H2U3iCqVZ1 via @YouTube

— Tim Nolan (@TimNolan1941) August 17, 2017

ESMO: Where will Merck, Eisai take Keytruda-Lenvima next? Ovarian and colorectal cancer could be good options, data show https://t.co/mjqD8dcsru

— cafepharma (@cafepharma) September 20, 2020

Chasing Merck, Eisai launches insomnia drug Dayvigo in Japan https://t.co/e3JM6pAqPX

— cafepharma (@cafepharma) July 7, 2020

https://twitter.com/LRamseu/status/1312391912956010498

Merck, Eisai's Keytruda-Lenvima combo stonewalled in liver cancer after Roche's first-in-class green light #livercancernews https://t.co/uJyJ0rpuoG

— Blue Faery (@BlueFaeryLiver) September 16, 2020

US rejects MSD/Eisai's Keytruda Lenvima combo https://t.co/U6bwJRTYcK #lifesciences #news

— PharmaTimes (@PharmaTimes) July 9, 2020

Merck, Eisai's Keytruda-Lenvima combo stonewalled in liver cancer after Roche's first-in-class green light https://t.co/fCgfHt2mPc

— FiercePharma (@FiercePharma) July 8, 2020

Merck, Eisai to put experimental cancer combination in new clinical trial https://t.co/LuQoPj699g

— MarketWatch (@MarketWatch) July 8, 2020

Merck, Eisai to put experimental cancer combination in new clinical trial https://t.co/uoyKGe8up0

— MMC Anchor (@MMCAnchor) July 8, 2020

ASCO: Merck, Eisai pad case for liver cancer nod with Keytruda-Lenvima combo data https://t.co/f6piWgmPOf

— EIPG (@EIPGeu) June 1, 2020

.@Merck/@Eisai's Keytruda/Lenvima combo 1st to win simultaneous approvals from @US_FDA, @GovCanHealth & @TGAgovau under new international regulatory program for #cancer drugs, writes @biotechvisigoth. $MRK #oncology https://t.co/nAfqQ8mUqL

— MedCity News (@medcitynews) September 18, 2019

New #paediatric treatments recently launched for #HIV #soiltransmittedhelminths #epilepsy and #pneumonia from 4 companies detailed in #atmi2018 today: @GSK @JNJNews @Merck @eisai …. #worldChildrensDay2018 #WorldChildrensDay https://t.co/qnb3DoC0m1

— Danny Edwards (@dannyjedwards) November 20, 2018

#Eisai, #MSD start marketing activity for #LENVIMA https://t.co/qGiJ2CwZx0 via @AsiaBioSpectrum

— Sudam Walekar (@sudam_walekar) October 23, 2018

Eisai and MSD Japan Commence Collaboration on Commercialization Activities for LENVIMA (Lenvatinib) in Japan https://t.co/oLX4MT3Vnu

— EIN Presswire: Merck Newswire (@EINMerckNews) October 22, 2018

Eisai/MSD’s Lenvima approved in Europe for liver cancer https://t.co/pPxoYTKCzG pic.twitter.com/Itatzdg438

— PIR International (@PIR_Intl) August 28, 2018

Merck, Eisai win FDA approval for Lenvima to treat unresectable HCC https://t.co/5tlVxTAiLO

— NGT Consulting (@NextGeneTherapy) August 20, 2018

Eisai and MSD team up to combine Lenvima and Keytruda in cancer https://t.co/K7XtG4RWnv pic.twitter.com/R9fukbkYeX

— Pharmamarketeer (@Pharmamarketeer) March 13, 2018

Merck partners with Eisai's Tyrosine Kinase inhibitor drug Lenvatinib with apotential deal of over 5 billion dollars#merck #Eisai #Checkpointinhibitor #Tyrosinerkinaseinhibitor #combination #billiondollar #deal #treat #malignancies https://t.co/NXsLRtc17N

— Neil Sankar (@SankarNeil) March 12, 2018

Merck and Eisai Ink $5.76B Cancer Deal https://t.co/bKH5FnuCC9 pic.twitter.com/RI1iJIIqLI

— Biotech World (@BiotechWorld) March 9, 2018

Eisai and MSD will jointly develop and commercialize a thyroid cancer therapy – https://t.co/Z1TfQSlksY pic.twitter.com/QVLB0ppzJT

— GMPnews.Net (@GMPnewsNet) March 8, 2018

Our final panel session at @PharEast2018 features Representatives from @JNJCares, Eisai Japan, MSD Singapore and Fosub-kite discussing on using real world evidence (RWD) to support the rational use of medicine in Asia. #phareast pic.twitter.com/LD4Y0kmqE4

— Phar-East (@PharEast2018) March 2, 2018

@gatesfoundation , @wellcometrust & @Mastercard Launch Initiative to Speed Development and Access to Therapies for COVID-19#COVID19TherapeuticsAccelerator #Covid19 https://t.co/ATA8tRBLc7 #BD #BI #Eisai #EliLilly #Gilead #GSK #JandJ #MSD #Merck #Novartis #Pfizer #Sanofi

— Claude Waddington (@Mr_C_Wadd) March 30, 2020

MSD and Eisai announce meaningful objective response rates for Keytruda+Lenvima combo in two cancer patient populations https://t.co/dRtWAbK5fk #pharma pic.twitter.com/2YDFuIMvrs

— Pharmafocus (@Pharmafocus) May 29, 2020

Eisai and MSD's Lenvima recommended for NHS Scotland in advanced or unresectable #LiverCancer https://t.co/bhdX1Yb5qR #cancer #pharma #NHS pic.twitter.com/H2qvj5SrrE

— Pharmafocus (@Pharmafocus) April 8, 2019

Thank you to our No One Fights Alone Virtual Gala Celebration sponsors, including Platinum Ribbon Sponsors, Amgen, Merck, Oncosec Immunotherapies, and Silver Ribbon Sponsors, Eisai and Immunomedics. Your generosity and support make it all possible. https://t.co/B8RsqHB5bW pic.twitter.com/KungeoGTTb

— TNBC Foundation (@TNBCFoundation) October 23, 2020

These pharma fleecers, including Takeda, Eisai, Merck, and Genentech, choose to sell their expensive oncology drugs in excessively large drug vials that lead to waste. They got my second #PharmaFleeceAward today.

— Senator Dick Durbin (@SenatorDurbin) March 14, 2019

Daiichi Sankyo signs clinical trial collaboration deal with Merck and Pfizer: Daiichi Sankyo has entered into a clinical trial collaboration agreement with Merck and Pfizer to evaluate the combination of its [fam-] trastuzumab deruxtecan (DS-8201) with… https://t.co/N83w7zGYxv

— cafepharma (@cafepharma) October 26, 2018

Daiichi-Merck partnership lines up Keytruda combo therapy https://t.co/YnoL7Sa9B6 pic.twitter.com/9Ocwq2ei5F

— JackLeckerman (@JackLeckerman) October 9, 2018

Daiichi Sankyo has entered into a clinical trial collaboration agreement with a subsidiary of MSD to evaluate a potential new combination therapy for breast or lung cancershttps://t.co/i08ieVPnZY pic.twitter.com/F3ZuKh8KUs

— Bio_Talent (@bio_talent) September 28, 2018

Unfortunately message is suspect bc of COI. F. Schiele reports personal fees from Board membership, consultancy, or lecturing from Sanofi, Amgen, Pfizer, AZ, MSD, BMS, Bayer & Daiichi-Sankyo. Steen Dalby Kristensen has recd lecture fees from AZ, Bayer, BMS/Pfizer and Boehringer- https://t.co/mKikYa72D9

— Ram Charan (@RamCharanji) January 11, 2018

Global Fibromyalgia Drugs market 2020: focuses on companies, opportunities, market size, growth, revenue & forecast 2026 | COVID19 Impact Analysis | Key Players: Pfizer, Eli Lilly, Actavis, Merck Sharp and Dohme, Daiichi Sankyo, etc. | InForGrowth – The … https://t.co/Z61iSQQlKs

— FMS News bot (@fmsbot) October 2, 2020

Hyperlipidemia Market: Market Data, Industry Analysis, Size,Share 2027 | Leading Players- AstraZeneca, Sanofi, Merck & Co., Pfizer, Daiichi Sankyo Company https://t.co/Wbz8agTS65

— Harshad Ramesh Borde (@BordeHarshad) August 25, 2020

The Next Boom Sector: Cancer

Physiomics #PYC is a leading oncology consultancy using its proprietary state of the art Virtual Tumour technology to predict and better understand effects of cancer treatments

Clients:
Merck, Astellas, Bicycle, Valirx, Cyclacel, CellCentric etc pic.twitter.com/djRsMNxJsc

— Stockonomist (@Stockonomist) September 28, 2020

Thanks to our @ANZUPtrials #bestofGUoncology #ANZUPGU19 sponsors – @IpsenGroup Astellas Oncology @AstraZeneca @MSD_Aus pic.twitter.com/WtTfQE1djd

— ANZUP (@ANZUPtrials) November 6, 2019

.@NICEComms has been busy with announcements today, rejecting Astellas’ #Xospata for a certain type of acute myeloid leukaemia (AML) and querying evidence for MSD's #Keytruda in head and neck cancer https://t.co/vFcLhQXJnT

— pharmaphorum (@pharmaphorum) January 15, 2020

MSD acquires Takeda’s Dunboyne manufacturing facility https://t.co/zOsjPUDhHN

— Silicon Republic (@siliconrepublic) August 10, 2020

MSD buys Takeda biologics medicines plant in Dunboyne https://t.co/IflH6PU1MF via @IrishTimesBiz

— Irish Times Business (@IrishTimesBiz) August 7, 2020

MSD to takeover Takeda's Dunboyne facility https://t.co/ACUOaUBlOd

— RTÉ Business (@RTEbusiness) August 7, 2020

This is a very welcome announcement from MSD and Takeda. https://t.co/C6aqYapp57

— Martin D Shanahan (@MartinDShanahan) August 7, 2020

Takeda acquired Tim Clackson's prev company, ARIAD, in '17 for $5.2 Billion. He had originally joined ARIAD in 1994. In addition to Takeda & Merck/MRL, German Merck's M Ventures & Ipsen's venture fund are also corporate VCs that invested in the B round. They moved 2 Waltham, MA https://t.co/OxT4HM5RxL

— Pearl Freier (@PearlF) March 2, 2020

Takeda & Merck (MRL Ventures) r 2 of the investors in #CambMA-based immuno-oncology Xilio Therapeutics fka Akrevia. $100.5M B. Originally launched by @atlasventure & F-Prime. CEO is @OtherReneRusso & Tim Clackson is Prez & EVP R&D.MRL Ventures @dud3k BOD https://t.co/JaUnc6UUXD

— Pearl Freier (@PearlF) March 2, 2020

Takeda, Merck invest in cancer startup's Xilio Therapeutics $100M Series B round – Bizwomen https://t.co/GBIVu54ivm #venturecapital #earlystageinvestors #angelinvestors #startups

— Red Trait Ventures (@RedTrait) March 4, 2020

PharmaScrip: Executives On The Move: Exits From Takeda Vaccines And Novartis Institutes To CMO Positions And Board Changes At Merck & Co. https://t.co/1Ah2xcjDQI #PharmaScrip https://t.co/3BT9hqerzu pic.twitter.com/ON8dj4Klug

— ZorgNL (@zorgnl) February 13, 2020

Impact of COVID-19 on Colorectal Cancer Therapeutics Market Latest trending report is booming globally by Top Leading Players Taiho Pharma, Merck KGaA, Amgen, Takeda https://t.co/Xud5IlkmE0

— mednetnews (@mednetnews) October 17, 2020

Colorectal Cancer Therapeutics Market 2020-2026 | Comprehensive Study COVID19 Impact Analysis | Worldwide Key Players: Taiho Pharma, Merck KGaA, Amgen, Takeda, Roche, etc. https://t.co/rJMqyCbJPm

— mednetnews (@mednetnews) September 5, 2020

Global Innovative Drug Market Expected to Reach highest CAGR: Pfizer,Gilead Sciences,Johnson & Johnson,Roche,AbbVie,Sanofi,Amgen,Novartis,Merck & Co. (MSD),GlaxoSmithKline (GSK),Bayer,Takeda,AstraZeneca,Novo Nordisk https://t.co/An4NCt3fo9

— @ReportsandMarkets (@ReportsMarkets) October 13, 2020

#VaccinesEurope represents drugmakers including #AstraZeneca, #GlaxoSmithKline, #Janssen (which belongs to Johnson & Johnson), #Merck, #Novavax, #Pfizer, #Sanofi, #Takeda, #Abbott and #CureVac. Covid-19 vaccine makers #LobbyEU for #LegalProtection.https://t.co/FNImlmq8yE

— Riikka Kevo (@riikka_kevo) August 26, 2020

Lipid Metabolism Disease Drug Market Latest updates and Coronavirus (COVID-19) Impact on Global Market in 2020-2029 Merck, Takeda Pharmaceutical and Novartis – The Loop 21 https://t.co/xazRpkLaZ2

— Dr Jitesh Arora (@drjitesharora) July 29, 2020

Who would want a simple solution?

"thank the leadership of AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Eisai, Eli Lilly, Evotec, Gilead, GlaxoSmithKline, Johnson & Johnson, KSQ Therapeutics, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, and Vir"https://t.co/V20z6DAu2U

— sandeep chakraborty (@sanchak74) June 12, 2020

Global #pharmaceuticals unprecedented collaboration in the search for effective #COVID19 therapies. IFPMA press conference on 30 April 2020 with key speakers across MSD, Takeda, CSL, Pfizer, AstraZeneca, Sandoz and Merck.https://t.co/Blg8sI0uHX @IFPMA @ThomasCueni @MedicinesAus

— Rozalina Sarkezians (@RozalinaRS) May 1, 2020

Pray to Merck, Pfizer, Sanofi, Takeda, J&J, Lilly. Pray to all the start up biotechnology firms throughout the world. Pray to science. An imaginary friend in the sky will not help you. https://t.co/jGz1Ga4fID

— The Grackle ☠ (@LanceMa89524580) March 20, 2020

Takeda, Merck invest in Waltham cancer startup's $100M round https://t.co/KOtqmEQWpy

— Matthew Liptak (@mattliptak) March 2, 2020

Global Drugs for Lipid Metabolism Disease Market 2020 Raises During Pandemic Phase 2021 | Merck, Novartis, Takeda Pharmaceutical – Best News Monitoring https://t.co/6mUdaMY12P

— Dr Jitesh Arora (@drjitesharora) July 29, 2020

Skyhawk Therapeutics, one of GGC's first portfolio companies, recognized by BostInno as one of the 20 Boston Startups to Watch in 2020! Great progress on HUGE dollar contracts with Celgene / Bristol-Myers Squibb, Biogen, Merck, Takeda and Genentech. https://t.co/cktw5pUivN

— Good Growth Capital (@goodgrowthvc) December 23, 2019

U.S.A. アメリカ Vol.122（New Jersey ニュージャージー州 Vol.3: pharmaceutical corporations 製薬会社）

All the below link and tweets are in English.

取り急ぎ以下貼っておきます。Vol.123（New Jersey ニュージャージー州 Vol.4: pharmaceutical corporations 製薬会社）もご覧ください。

New Jersey Vol.10 (corporations: Merck (Merck Sharp & Dohme (MSD) outside the U.S. & Canada))

上記リンク内に無い本日までのツイート

Earlier this week at the #HLTH2020 virtual conference, Mike Nally and Dr. Julie Gerberding spoke about #COVID19 and the importance of building trust within the community. pic.twitter.com/apenJ82Pt6

— Merck (@Merck) October 15, 2020

Learn more about our latest #infectiousdiseases update being announced during #IDWeek2020: https://t.co/Y8iz2dQfDG $MRK pic.twitter.com/NZNdVVG0Md

— Merck (@Merck) October 21, 2020

“@Merck executives, some of whom have been skeptical of unproven technologies some rivals are using in their #vaccines, have noted in public that their own #COVID19 vaccines rely on proven technologies currently used to fight other diseases.” #compliance #competition #IP #Pharma https://t.co/cWNZDFVm06

— Mark Warner (@MAAWLAW) October 23, 2020

.@Merck, one of the largest pharmaceutical companies in the world, is testing the delivery of vaccines via drone to get them to patients fasterhttps://t.co/NGgvfI9QvH

— FierceHealthIT (@FierceHealthIT) October 23, 2020

BIO-BREAKING: @IAVI, @SerumInstIndia & @Merck have joined hands to develop #SARSCoV2 neutralizing monoclonal antibodies (#mAbs) co-invented by IAVI and @scrippsresearch as innovative interventions to address the #COVID19 pandemic.

More: https://t.co/BIr9fn9uq2 via @BioVoiceNews

— BioVoice (@BiovoiceNews) October 23, 2020

Quite an intriguing account of the dynamics leading to Oxford U's (and its for-profit spin-offs') deal with @AstraZeneca (vs @Merck) re research, development, distribution, and pricing of a hoped-for vaccine.https://t.co/uqEOle6whi

— Alani Golanski (@alanigolanski) October 22, 2020

We’re at #IDWeek2020, presenting data on combination #vaccines with @Merck. Read more about the presentations here: https://t.co/fISWZ4h4aG pic.twitter.com/IHbGFg2CM4

— Sanofi US (@SanofiUS) October 20, 2020

@volans_i , @Merck and @Vidant_Health team up to bring the future of healthcare one step closer with the 1st ever temperature-controlled drone medicine and vaccine delivery program in the United States! https://t.co/RpFtJZhXto

— Volansi (@volans_i) October 20, 2020

When John contracted #COVID19, our community stepped up to help in incredible ways. Learn how the support and compassion he received made a powerful difference. #PatientsAreOurPurpose

— MSD (@MSDInvents) October 9, 2020

https://twitter.com/FriendsOfSheba/status/1318279650842464259

As leaders convene for #IDWeek2020, we are committed to collaborating with the scientific community and investing our expertise and resources to address global antimicrobial health issues. Learn more: https://t.co/tDe64Bdmer pic.twitter.com/AbFsjVmAM5

— Merck (@Merck) October 21, 2020

"Clark, thanks for giving me eyes. Thanks for donating your life for the sake of mine. We don’t walk the streets; we fly!” Hear more from our own Darley Oliveira who has been blind since childhood & how his guide dog, Clark is helping him break down barriers. #PoweredbyInclusion

— Merck (@Merck) October 15, 2020

#DYK there’s a field where technology can help determine what the next big thing in pharmaceuticals could be? Hear inspiring messages from our #WomenInSTEM to encourage the next generation of inventors. #NationalSTEMDay pic.twitter.com/WrU8PzjmxB

— Merck (@Merck) November 8, 2019

Through the 2019 Fellowship for Global Health, a select group of our determined inventors will bring their diverse set of skills to locations in need of specific healthcare solutions. Follow the Fellows as they begin their ambitious journeys across the globe. #FellowInventors

— Merck (@Merck) October 1, 2019

We’re excited to be (virtually!) joining healthcare professionals from across the country at #NPWH2020. Click here to learn more about how you can help grow the conversation about her birth control options: https://t.co/O8KIUcO9uU pic.twitter.com/w1ZiylDlOD

— US Merck Products (@USMerckProducts) October 1, 2020

We’re excited to be (virtually!) joining healthcare professionals from across the country at #AAFPFMX. Click here to learn more about how you can help grow the conversation about her birth control options: https://t.co/bjIRYqEGNf pic.twitter.com/70IjkRENQV

— US Merck Products (@USMerckProducts) October 1, 2020

September is Gynecologic Cancer Awareness Month—talk to your patients about a treatment option for certain types of #EndometrialCarcinoma. Learn more: https://t.co/j1drUEdg6C pic.twitter.com/IjGj8p8LEO

— US Merck Products (@USMerckProducts) September 16, 2020

Biosimilars offer doctors more treatment options, and that may create more competition. #Biosimilars may help more people get access to biologic medicines. They may also help reduce costs in the health care system. https://t.co/5UL4ySDr7p pic.twitter.com/k9H7Yf1vuH

— US Merck Products (@USMerckProducts) September 2, 2020

Check your skin for melanoma. It's important! pic.twitter.com/TQVR7hN1as

— US Merck Products (@USMerckProducts) August 12, 2020

Check your skin for melanoma. It's important! pic.twitter.com/euc7ldQppS

— US Merck Products (@USMerckProducts) August 12, 2020

Take a closer look at ZINPLAVA™ (bezlotoxumab) in Washington, DC. Visit booth 410. pic.twitter.com/POUHwRC60t

— US Merck Products (@USMerckProducts) October 1, 2019

We’re here getting prepped for the first day of American Diabetes Association 2019 Scientific Sessions! Stop by Booth 1525 tomorrow when ADA 2019 kicks off. pic.twitter.com/bmbztGrQG9

— US Merck Products (@USMerckProducts) June 6, 2019

Hello, Music City! We’re excited to be joining OB-GYNs from across the country at ACOG. pic.twitter.com/AvhJ4xh7MJ

— US Merck Products (@USMerckProducts) April 26, 2019

Fourteen years ago this month, I was sworn in as @HHSGov Deputy Secretary. Very grateful @POTUS gave me the opportunity to come back to this amazing department to serve the American people – it’s the honor of a lifetime. pic.twitter.com/lH7flhQzhO

— Secretary Alex Azar (@SecAzar) July 28, 2019

“Over the course of my career, I’ve been touched by so many women bravely battling triple-negative #breastcancer.” Dr. Gursel Aktan shares what drives her to pursue #breastcancer research. #BCAM

— MSD (@MSDInvents) October 23, 2020

We're proud to unveil our next center of innovation – the London Discovery Research Centre. This state-of-the-art facility will become our research and business hub in the heart of London’s “Knowledge Quarter.” Learn more. #InventingForLife

— MSD (@MSDInvents) October 13, 2020

NICE recommends @Merck’s Keytruda for untreated metastatic or unresectable recurrent #headandneck squamous cell #carcinoma, but only as monotherapy, creating division in access within UK https://t.co/0ViUMLd329

— pharmaphorum (@pharmaphorum) October 23, 2020

Phase 3 trials in adults bolster @Merck challenge to @Pfizer’s Prevnar 13 vaccine to prevent pneumococcal disease, and keep filing before year-end on track https://t.co/f8DGI7kTcA

— pharmaphorum (@pharmaphorum) October 21, 2020

This #BCAM, I encourage you to listen to Paula Schneider, @susangkomen CEO & breast cancer survivor, as she reflects on her cancer experience in a #WithLoveMe letter. Hear other inspirational stories & explore resources at @Merck’s Your Cancer Story: https://t.co/3nYsDCwZA1 pic.twitter.com/mHIfxSo6cv

— Katie Couric (@katiecouric) October 21, 2020

Merck announced positive data regarding 2 studies, one examining pembrolizumab in combination with chemotherapy and another in combination with quavonlimab in combination to treat advanced non-small cell lung cancer. | @Merck https://t.co/uj7MTofcwf

— Cancer Network (@CancerNetwrk) October 20, 2020

.@Merck Receives Excellence in Health & Well-Being award from Business Group on Health https://t.co/09aeVV41Ak pic.twitter.com/tYLA3jh4Cf

— 3BL Media News (@3BLNews) October 15, 2020

@US_FDA expands Keytruda @Merck approval for classical Hodgkin lymphoma https://t.co/ddhDIHTGDJ pic.twitter.com/z5qokOweQs

— HemOnc Today (@HemOncToday) October 15, 2020

Experimental Antiretroviral Has Potential for Once-Weekly HIV Treatment #NNRTI #HIV #mk8507 #antiretrovirals #UequalsU #Glasgow2020 #islatravir @Univ_Paris @pozmagazine @pozglobal @JHUNursing @MDHealthDept @BMore_Healthy @BaltCityLGBTQ @lgbtqnation @Merck https://t.co/vZMCGvj3sr

— REACH Initiative (@HopkinsREACH) October 21, 2020

Support for melanoma patients-'Melanoma Matters' is 4-part patient support video series. A video & resources will be released weekly. See more & stories to come: https://t.co/TNTrgFtkkx. Thanks to melanoma support groups, @melanomasupport, @PeterMacCC & @bmsnews @Novartis @Merck

— Melanoma Institute (@MelanomaAus) October 23, 2020

No matter where you are in your #cancer journey, no one should have to walk alone. Check out the latest #melanoma resources on @Merck’s cancer support program, Your Cancer Story, developed to help patients & caregivers from diagnosis through survivorship, & beyond. #MerckPartner pic.twitter.com/mbqLrKPNQI

— Melanoma Research (@MelanomaReAlli) October 15, 2020

Keytruda (@Merck) has received an expanded label use from @FDAOncology as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma. https://t.co/wKkASOdmKf pic.twitter.com/RRCdGdShZI

— The Cancer Letter (@TheCancerLetter) October 20, 2020

Bristol Myers, Exelixis get in FDA fast lane for Opdivo-Cabometyx combo in kidney cancer | @Bristol_Myers @ExelixisInc @Merck @pfizer #Cancer #kidneycancer #renalcellcarcinoma #NewYorkCity #Alameda #California #NewJersey #Biotech https://t.co/teZXz0JZxk

— Pharm2Market (@pharm2market) October 21, 2020

@AmerUrological @Merck announced plans to construct a new TICE BCG manufacturing facility in the USA and anticipates the build to take up to 6yrs to complete.

expects 3x its current capacity.

Until, Merck has no plans to change the current dosing of BCG pic.twitter.com/iMDYZogO56

— @DocMeetings – Urology (@docmeetings) October 20, 2020

Check out part 2 of @Okerainc CEO @NickHalsey's discussion with @Merck's Chief Data & Analytics Officer Sol Rashidi on her journey to becoming a #CDO and the evolving role for #CDOMagazine's #TechTalks. Check it out here —> https://t.co/NyfRoQkXXb

— Okera (@okerainc) October 19, 2020

FDA puts ‘black box’ warning on popular asthma medication; teens speak out about side effects https://t.co/b8qp15Kccb @USMerckProducts @USMerckProducts @Merck

— Donnie USMC (@don2569603) September 9, 2020

Getting ready for a FB Live today 1pm/2pm CST/EST: 7 Things Women Should Know About Heart Failure. Through partnership w/ @AAHFN and sponsorship by @Amgen @Novartis @Cytokinetics @AstraZenecaUS & @USMerckProducts, experts discuss risks you might not know. https://t.co/e75amFOG4H pic.twitter.com/Mbg5p7RMCi

— WomenHeart (@WomenHeartOrg) June 28, 2019

How can #data and action can drive improvement in D&I? Join our #paneldiscussion at #HRTechConf moderated @slupusho who will talk to our customers at @Merck, @Panasonic, and @Uber about how data and #analytics enables them to move the needle on D&I. https://t.co/5Li46RolKJ pic.twitter.com/W5A4LScbMG

— Visier (@visier) October 23, 2020

Thank you @Merck for being an #AMWA2020 celebratory sponsor and exhibitor! We appreciate your partnership and support. https://t.co/v1VoQ3BNIK pic.twitter.com/mvcOW9CHUT

— AMWA (@AmMedWriters) October 23, 2020

MDP is proud to work with @Merck to ensure our work toward #riverblindness and #lymphaticfilariasis elimination can continue safely during the #COVID19 pandemic. https://t.co/ass7B42Kei

— Mectizan Donation Program (@MectizanMDP) October 22, 2020

.@Merck donates $500K to #NGOs working to eliminate #RiverBlindness (#onchocerciasis) & lymphatic #filariasis

Funds to be administered by @MectizanMDP & address suspensions of #CommunityHealth interventions due to #COVID19 https://t.co/qASLxxFNYg #parasitology #GlobalHealth pic.twitter.com/lKoJQpboBJ

— DDNews Online (@DDNewsOnline) October 22, 2020

See yourself in STEM. Biotechnology alumna Monica Roberson shares how her experience with STEM Mentorship Partner @Merck prepared her for graduate school and beyond. Learn more at https://t.co/q1DYfpprrS #BHCCSTEM #MassSTEMWeek #MACommCollege #CommunityCollege pic.twitter.com/0Q2vF2RF9Z

— BHCC Boston (@BHCCBoston) October 22, 2020

https://twitter.com/APSForg/status/1318913714825940992

We are proud to announce our #internalcommunications work with @Merck has received honorable mention in @PRSANJ's Pyramid Awards! We worked with our client to develop and execute an #employeeengagement campaign that raised money for cancer research. Great job, team! pic.twitter.com/eeQXUe6YkB

— The SPI Group (@spigroup) October 21, 2020

Thanks to our Bronze Sponsors @Merck and @genentech for their support of our event, "Health Equity in the Fight to End Cancer in Rural Montana." pic.twitter.com/nHHb1iq6mV

— ACS CAN Montana (@ACSCANMT) October 21, 2020

$ENZC penny Flippers Gonna regret selling ANY Shares these next 6 months!! @BioClonetics is Arriving @#BioPharma is Taking Notice! Look at those Numbers! Who will get us in #Partnerships READ THIS LINK: https://t.co/AqcZQD7upT I like @Merck & #AI like @BioClonetics Also $GLD #HIV pic.twitter.com/4omlyuWN9A

— Mike (@crabbermike) October 21, 2020

U.S.A. アメリカ Vol.119（California カリフォルニア州 Vol.3: pharmaceutical corporations 製薬会社）

All the below link and tweets are in English.

取り急ぎ以下貼っておきます。
California Vol.26 (corporations: Gilead Sciences)

上記リンク内に無い本日までのツイート

Read an open letter from our Chief Medical Officer about today's @US_FDA approval of our antiviral treatment for COVID-19. https://t.co/JAyK3zJGD7

— Gilead Sciences (@GileadSciences) October 22, 2020

The @US_FDA today approved our antiviral to treat patients with COVID-19 requiring hospitalization. Read more: https://t.co/Z5lO227KVU. pic.twitter.com/NqebDeoWBv

— Gilead Sciences (@GileadSciences) October 22, 2020

We released the following statement today related to the WHO SOLIDARITY trial for the treatment of COVID-19 https://t.co/YzAy1EgnVV.

— Gilead Sciences (@GileadSciences) October 16, 2020

.@US_FDA gave its final nod to @GileadSciences #Remdesivir for treating hospitalised Covid-19 patients. @viswanath_pilla reports. #COVI19 #CoronavirusIndia #COVIDIndia https://t.co/zX7bUsJSES

— moneycontrol (@moneycontrolcom) October 23, 2020

5 Penny Stocks To Watch After Gilead Sciences' Big Remdesivir News https://t.co/fze9H7hBwI

— EIN Presswire: Lung Cancer Newswire (@EINLungCancer) October 23, 2020

NEW: Gilead Sciences has announced that the FDA has approved remdesivir for treating COVID-19. The antiviral drug becomes the first drug to receive full approval from the FDA for treatment against the coronavirus, according to the pharmaceutical company. https://t.co/FGiIkZOtPk pic.twitter.com/m9XIdaVMsE

— WebMD (@WebMD) October 22, 2020

NEW: FDA approves remdesivir to treat Covid-19, making it the first and only drug so far to have received federal approval for the coronavirus. https://t.co/NddlmHEfOo

— MSNBC (@MSNBC) October 22, 2020

BREAKING: FDA approves first COVID-19 drug, remdesivir https://t.co/C5outLVVNF

— CBS News (@CBSNews) October 22, 2020

BREAKING: FDA approves Gilead's remdesivir as coronavirus treatment https://t.co/ryNKPD9vhB

— CNBC Now (@CNBCnow) October 22, 2020

Remdesivir receives FDA approval to treat hospitalized COVID patients @drsanjaygupta reports pic.twitter.com/OxqCn3RKdM

— The Lead CNN (@TheLeadCNN) October 22, 2020

JUST IN: The US Food and Drug Administration has approved remdesivir for the treatment of coronavirus infection, the drug’s maker, Gilead Sciences, says https://t.co/8pg6cHwRoB

— CNN (@CNN) October 22, 2020

Remdesivir is the first and only fully FDA-approved drug in the U.S. for treating the coronavirus. https://t.co/dtYQNytzch

— Axios (@axios) October 22, 2020

The news has barely mentioned it, but Big Pharma company Gilead is charging $3,000 for a coronavirus drug that costs them less than $10 to produce.

Once again, they're set to profit on the people's dime.

— Robert Reich (@RBReich) October 21, 2020

NEW: Gilead Sciences just received FDA approval for remdesivir. This is the inside story of how the company prepared for the pandemic https://t.co/VPXM3GjcbM pic.twitter.com/M4vwD8lNcD

— Businessweek (@BW) October 22, 2020

FDA just approved the first COVID-19 drug AND it's from @OceansideBiz-based@GileadSciences
Details here: https://t.co/pX2vmc6ZiT?

— Innovate78 (@Innovate_78) October 22, 2020

@CityofOceanside's @GileadSciences #COVID19 drug now @US_FDA approved! https://t.co/jYYZjfIVNC

— San Diego North EDC (@SDNorthEDC) October 22, 2020

https://twitter.com/SDRegionalEDC/status/1319400169650073600

Morning Bell: #ASX200 to open flat with all eyes on the #USPresidentialDebate2020 at 11am AEDT. U.S. FDA approves @GileadSciences' #COVID19 treatment. Trading ideas: $ALL, $LBY, $AIS, $NGI, $MYQ & $TSO. #ausbiz #belldirect #tradingideas https://t.co/xblREmVKkU

— Bell Direct (@belldirect) October 22, 2020

The @US_FDA has approved the first drug treatment for #COVID19 in the US, and antiviral by @GileadSciences #remdesivir https://t.co/lrYd1NB3gq pic.twitter.com/byXuRUa4Pe

— Pharmacy Times (@Pharmacy_Times) October 22, 2020

.@US_FDA approves @GileadSciences's remdesivir as the first and only fully FDA-approved drug in the U.S. for treating the coronavirus.https://t.co/QbzL80S6oN #optometry #COVID19 #remdesivir pic.twitter.com/rcDZewIRgk

— Optometry Times (@OptometryTimes) October 22, 2020

#BREAKING Remdesivir becomes first FDA fully-approved coronavirus treatment https://t.co/VAwD4PgPZI

— KTNV 13 Action News (@KTNV) October 22, 2020

Thank you to @GileadSciences for choosing PPD to help support the clinical development program of your important new COVID-19 treatment. https://t.co/xuzXL3Cqpy #ppd #covid19 #coronavirus #pandemic #followthescience #wereinthistogether #wegotthis #relentless #collaborate pic.twitter.com/81yZNEFNcC

— PPD (@PPDCRO) October 22, 2020

ICYMI: The FDA approved Remdesivir for the treatment of coronavirus infection, says the drug's maker, Gilead Sciences. https://t.co/TMDKdaRrw4

— CBS46 (@cbs46) October 23, 2020

JUST IN: The FDA has approved Gilead Sciences’ antiviral drug remdesivir as a treatment for the coronavirus. Remdesivir is now the first and only fully approved treatment in the U.S. https://t.co/tdD2A5IkDB

— NBC Bay Area (@nbcbayarea) October 22, 2020

The FDA has approved #remdesivir for the treatment of #COVID19, Bay Area-based Gilead Sciences, said Thursday. https://t.co/Wix6PGn7vw

— ABC7 News (@abc7newsbayarea) October 22, 2020

JUST IN: The FDA has officially approved remdesivir as a treatment for coronavirus, drug manufacturer Gilead Sciences announced.https://t.co/MZtO88r2eS

— New York Daily News (@NYDailyNews) October 22, 2020

The @NIH has paused a phase 3 study on @LillyPad’s #Covid19antibody treatment on a potential safety concern. The #NIH-sponsored study is testing bamlanivimab (LYCoV555) in combination with @GileadSciences’s #Remdesivir in hospitalized patients. https://t.co/bip662pVW9

— CHEManager International (@CHEManager_EU) October 22, 2020

.@GileadSciences’ Remdesivir Flunks WHO Trial, Gains “Prequalified” Status. Learn more:https://t.co/4LWvAJnhMb pic.twitter.com/xDLUSFqesK

— Genetic Engineering & Biotechnology News (@GENbio) October 19, 2020

News for #pharma #marketers: Mon, Oct 19

-More than 25% of state legislators accepted pharma campaign contributions since 2019
– @Pfizer won’t seek emergency authorization of vaccine until late Nov.
– @GileadSciences Remdesivir failed to prevent deathshttps://t.co/IAaXOVHudQ

— MM+M Magazine (@MMMnews) October 19, 2020

ICYMI: Future of Gilead's #remdesivir for COVID-19 in doubt after WHO reveals trial data @GileadSciences #covid19 #WHO https://t.co/4j6ij1AD6j pic.twitter.com/Ex8jNDr631

— Market Intelligence: Healthcare (@SPGMIHealthcare) October 19, 2020

WHO trial shows @GileadSciences Veklury (remdesivir) has no effect on mortality and hospital stay in COVID-19 – data is inconsistent with US studies used to support Emergency Use Authorization https://t.co/4LZOdhzd8J

— pharmaphorum (@pharmaphorum) October 16, 2020

Results from the WHO’s highly anticipated Solidarity trial found that none of the treatments ‘substantially affected mortality’ or reduced the need to ventilate patients, according to a copy of the study seen by the FT https://t.co/yuKtO8sojn pic.twitter.com/LegWL7ryGI

— Financial Times (@FinancialTimes) October 15, 2020

The US Food and Drug Administration has approved the first drug to treat COVID-19 – Remdesivir. Gilead Sciences Inc says the antiviral medicine, given through an IV for patients needing hospitalisation, cut the time for recovery by five days — from 15 days to 10 on average. pic.twitter.com/gJ5TfeROoY

— Jamaica Gleaner (@JamaicaGleaner) October 22, 2020

@US_FDA approves Gilead’s Remdesivir to treat #COVID19, even though @WHO's study found drug not effective @DrTedros @realDonaldTrump @JoeBiden @KamalaHarris @Mike_Pence @CDCgov @AfricaCDC @NIH @GileadSciences #Election2020 https://t.co/AxP8HjKLz0 via @todaynewsafrica

— TODAY NEWS AFRICA (@todaynewsafrica) October 22, 2020

Investors betting on big profits from #COVID19 treatments may get an unwelcome surprise when @GileadSciences reports quarterly results this month as remdesivir, the first important coronavirus treatment, has not been used as much as first expected. https://t.co/R9ywTIGL7T pic.twitter.com/aiINMXzsuE

— Arab News Japan (@ArabNewsjp) October 17, 2020

FDA approves Gilead Sciences' antiviral drug for treating patients hospitalized with COVID-19. https://t.co/RMKapXSqij

— Arutz Sheva (@ArutzSheva_En) October 22, 2020

Remdesivir has very little effect on Covid-19 mortality, WHO finds https://t.co/ehhGOoTtVV

— The Guardian (@guardian) October 16, 2020

So, has #remdesivir shown a survival benefit? I remember @icer_review suggested that without a survival benefit the price should be about $310. The drug costs $3,120 now. Am I missing something or are we getting price-gouged (again) by @GileadSciences?

— Gregg Gonsalves (@gregggonsalves) October 16, 2020

Gilead received the Solidarity manuscript ruling out a big impact from remdesivir on #covid19 mortality on 28 September according to @WHO.

On 8 October, before the results became public, Gilead signed a billion dollar deal with the EU Commission for remdesivir.

I have questions

— Kai Kupferschmidt (@kakape) October 16, 2020

As #IDWeek2020 spotlights the impact of the #COVID19 pandemic on fighting #HIV, learn how our CARES Grantee Fund is supporting community organizations during this difficult time.

— Gilead Sciences (@GileadSciences) October 22, 2020

The data presented at #IDWeek2020 highlight our commitment and efforts to assess and address unmet needs in #HIV treatment. Learn more here: https://t.co/7p4UfPVE9v pic.twitter.com/OCWbVbaH99

— Gilead Sciences (@GileadSciences) October 21, 2020

#HIV is not a crime. Those living with and at risk for HIV are often held back by laws that discourage people from getting tested or treated.

Learn more from Health Not Prisons Collective, who joined the panel discussion at #2020USCHA.

— Gilead Sciences (@GileadSciences) October 20, 2020

#HealthDisparities can prevent access to HIV care and treatment in Black communities. Progress in ending the #HIV epidemic means not leaving anyone behind.

Join our conversation at #2020USCHA around ending health disparities in HIV.

— Gilead Sciences (@GileadSciences) October 19, 2020

“Peer-to-peer programs work because there’s nothing unreal about it. It’s raw and it’s truth.” Tune in to the #Hepcast, made in collaboration with @Hep_Alliance, to hear how Tony McClure of @HepatitisCTrust helps engage people living with #hepatitisC.

— Gilead Sciences (@GileadSciences) October 16, 2020

This National Latinx AIDS Awareness Day, meet Bamby Salcedo, founder of @TransLatina_C and an advocate for #HIV awareness and prevention. #NLAAD

— Gilead Sciences (@GileadSciences) October 15, 2020

ツイッター検索で上記製薬会社名及び Japan や日本の5製薬会社各社名を入れて出て来たもの

Japan's health ministry included dexamethasone as an option for treatment along with Gilead Sciences Inc's antiviral drug remdesivir. #Japan #Coronavirus #CoronavirusVaccine https://t.co/VM96hBlMJo

— IndiaToday (@IndiaToday) July 22, 2020

Japan on Thursday approved Gilead Sciences Inc's remdesivir as a treatment for COVID-19, making it the country's first officially authorized drug to tackle the coronavirus disease. https://t.co/oZggDtgDyq

— GMA News (@gmanews) May 7, 2020

Japan approves Gilead Sciences' remdesivir as COVID-19 drug https://t.co/EP6Brqywfb pic.twitter.com/7UeR0czgl2

— Reuters (@Reuters) May 7, 2020

Japan approves Gilead Sciences' #Remdesivir as #COVID19 drug. $GILD https://t.co/lJeYKLbitp

— Bio Stocks™ (@BioStocks) May 7, 2020

"Japan on Saturday began to fast-track the approval of remdesivir, Gilead Sciences' antiviral drug intended to treat coronavirus patients… It has also asked the U.S. to ensure Japan receives adequate supplies of the drug."https://t.co/bqxF9ODV9I

— DUTERTENOMICS (@Dutertenomics) May 2, 2020

https://twitter.com/FinancialTimes/status/1258289223121043456

#SunStarWorldNews
TOKYO — Japan has approved Gilead Sciences’ antiviral drug remdesivir for coronavirus treatment in a fast-track review just four days after the US company submitted an application.https://t.co/YoDxFOMWR4

— Sun Star Davao (@SunStarDavao) May 8, 2020

U.S. drugmaker Gilead has an experimental antiviral drug that may work against the coronavirus. It's unapproved for use in humans, but hey it appears to have worked on the first U.S. infection case in Washington state.@joewalkerWSJ https://t.co/zjXUG7rAJY

— Jonathan Cheng (@JChengWSJ) February 1, 2020

Gilead Sciences and Japan Tobacco signed a letter of intent to dissolve their licensing partnership, the cigarette company said Monday, as the U.S. drugmaker prepares to market a new HIV treatment in Japan on its own. https://t.co/WhK2ynVZpX MT @NAR pic.twitter.com/WnfoUz4J9d

— HIV Insight (@HIV_Insight) September 1, 2018

Gilead and Eisai announce co-promotion agreement for investigational rheumatoid arthritis treatment in Japan: https://t.co/ia8aFkxONY.

— Gilead Sciences (@GileadSciences) December 24, 2019

SFBN Feed: Jyseleca® (Filgotinib) Approved in Japan for Rheumatoid Arthritis: FOSTER CITY, Calif. & TOKYO–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Eisai Co., Ltd. (Tokyo, Japan) today … #BayArea #Biotech https://t.co/y7JaL4nXwM

— San Francisco Biotechnology Network (@sfbionetwork) September 25, 2020

Gilead Sciences and Eisai Agreed on Distribution and Co-Promotion of Filgotinib – https://t.co/xHtO20gxBa pic.twitter.com/8XM09CgNkO

— GMPnews.Net (@GMPnewsNet) December 30, 2019

Gilead Signs a Co-Promotion Agreement with Eisai for Filgotinib in Japan @GileadSciences @EisaiUS
https://t.co/92Bp0R5v30

— PharmaShots – Incisive news in 3 shots (@Pharmashot) December 26, 2019